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ABSTRACT
1. hCG has been reported to have weak thyrotropic activity when
tested in various bioassay systems and conditions associated with high hCG
production, including normal pregnancy and hyperemesis gravidarum, have been
reported to be associated with hyperthyroxinaemia. The hyperthyroxinaemia may
be severe, with the patient displaying clinical signs of thyrotoxicosis, but often
the increase in thyroid function is mild with no clinical evidence of thyrotoxicosis,
ie, euthyroid hyperthyroxinaemia. hCG is suspected as a causal factor of the
hyperthyroxinaemia in these patients and also as a possible aetiological factor in
the development of hyperemesis gravidarum, a syndrome of intractable, severe
vomiting in early pregnancy. This study was designed to investigate the
thyrotropic activity of hCG in women suffering from hyperemesis gravidarum and
to relate this to thyroid function in these women.
2. Serum levels of hCG, total thyroxine (T4) and thyroid
stimulating hormone (TSH) were measured in 58 patients suffering from
hyperemesis gravidarum. Urine was collected from 17 of these patients and the
thyrotropic activity of urinary hCG studied before and after purification of the
hCG by sequential affinity, gel-filtration and ion-exchange chromatography. The
purified material, termed 'eluate', and an aliquot of unprocessed urine were
dialysed, freeze-dried and the thyrotropic activity of each sample measured using
an FRTL-5 bioassay system and a recently developed growth-response signal
termed ESTA (Eluted STain Assay). Urine and serum hCG were measured using
an enzyme-immunoassay method specific for dimer hCG, T4 was measured by
an EMIT method and TSH was measured using an ultra-sensitive
chemiluminescent method. The FRTL-5 bioassay was chosen mainly because of
its availability and because of lack of a suitable human thyroid cell-line.
3. The FRTL-5 bioassay system with the ESTA response signal
proved to be simple to use and showed good precision (CV10%). The cells
were not affected by dialysed urine containing no hCG and an unequivocal
response was seen with highly purified hCG, partially purified hCG and crude
hCG, as well as with bovine and human TSH. The approximate potency ratios of
bTSH mU:hTSH mIU:hCG IU in this system were found to be 1:7:35,000,
implying that a serum hCG concentration of 25,000 IU/I could, theoretically,
emulate the thyroid stimulating activity of 5 mIU/I TSH. More than one third of
the 58 patients studied were found to have high T4 levels and low TSH levels and
there was significant correlation between serum hCG and these thyroid function
indices. However, although those women with high T4 and/or low TSH as a
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group had significantly higher serum hCG levels than the euthyroid group, there
were individual patients with high hCG and normal T4, while others who had
relatively modest hCG levels had hyperthyroxinaemia. All the urine and eluate
samples from hyperthyroxinaemic patients showed measurable thyrotropic activity
in the bioassay. No measurable response in the bioassay was obtained on samples
from five women who had a normal T4. The actual relationship between hCG and
thyroid function in hyperemesis gravidarum is still unclear, but there appears to be
individual differences in the thyrotropic activity of hCG from different women,
and this, taken with the significant correlation found between serum hCG levels
and thyroid function, implies that hCG has a role in the development of transient,
pregnancy-associated hyperthyroxinaemia but that the relationship may be one of
individual determination, ie, that the thyrotropic activity of hCG varies between
and, perhaps, within individual women.
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Chapter 1 INTRODUCTION
Hyperemesis gravidarum is an uncommon syndrome of early pregnancy
characterised by intractable severe vomiting (1,2). The aetiology of hyperemesis
gravidarum is as yet unknown, but human chorionic gonadotropin (hCG) has for
many years been a suspected causal factor due to the coincidence of the peak
hCG-production time and the gestation period during which hyperemesis
gravidarum, and indeed the very common normal pregnancy-associated syndrome
of 'morning sickness', develops (1-11), hCG is normally produced in quantity
only during pregnancy (3,8,9,12) and has been shown to have weak thyrotropic
activity when tested in various in-vitro and in-vivo bioassay systems (13-21).
There have been many reports of patients with conditions associated with
physiologically (22-29) or pathologically (30-38) high hCG levels, including
hyperemesis gravidarum and gestational trophoblastic disease, developing
thyrotoxicosis. In the case of pregnant patients, the thyroid disturbance appears to
be transient (22,25,26) and patients show a spontaneous recovery of normal
thyroid function as the pregnancy advances into the second or third trimester, a
time when hCG levels in serum are approximately 10% of their peak, first
trimester levels (3,8).
One third or more of hyperemetic women have been found to have
hyperthyroximaemia (36,39,40) which may or may not be associated with clinical
thyrotoxicosis in addition, vomiting, the characteristic feature of hyperemesis
gravidarum, may be the presenting feature of thyrotoxicosis (41). The question
therefore arises: is hCG, due to its weak thyrotropic activity, responsible for the
thyroid over-stimulation in these patients and so, through this, the hyperemesis
itself? This leads to further questions, namely: do women with hyperemesis
produce more hCG per se, is it a more thyrotropic form or do these women have
greater overall thyrotropic stimulation due to a combination of potency and
quantity of hCG in their circulation?
This research project was designed to address the question or possiwe currerences
in thyrotropic activity of hCG in women with hyperemesis gravidarum. Urine
from these patients was subjected to a purification process to extract and purify the
hCG and the final product was tested for thyrotropic activity using an FRTL-5
cell-line bioassay system (42,43). Dialysed, but otherwise untreated, urine from
these patients was also tested for thyrotropic activity. The results obtained by the
bioassay were expressed as units of 'apparent hCG' and compared to the known
immunoreactive hCG content which had been previously measured by an
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enzyme-immunometric method (44). The apparent/measured ratio, or potency, of
hCG and the combination of potency and quantity of hCG (the
apparent/measured hCG multiplied by the serum hCG concentration) were then
correlated with the patient's serum total thyroxine, TSH and hCG and with the
gestational age at the time of sampling.
These results and relationships were then examined to test the hypothesis that
women with hyperemesis gravidarum have overstimulation of the thyroid due to
hCG- more hCG per se, a more thyrotropic form of hCG or a combination of
both.
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2.1. Human Chorionic Gonadotropin (hCG
2.1.a. Structure and Physico-chernical Characteristics of hCG
hCG is a glycoprotein hormone, similar in structure to the pituitary glycoprotein
hormones LH, FSH and TSH. The physico-chemical and immunological
characteristics of hCG have been the subject of many studies over the past twenty
years, and there is now general agreement regarding the structure and chemical
properties of the hormone (8,9,17,45-67).
hCG contains approximately 30% carbohydrate, has a molecular weight of 36,700
daltons and is a dimer molecule consisting of one alpha and one beta subunit
joined non-covalently. The major isoelectric point of hCG has been reported to be
4.2, but variation in the isoelectric point between 3.6 and 6.7 is found, reflecting
differences in carbohydrate content (19,48,49,53,55).
hCG dissociates into free alpha and beta subunits when incubated in 8 mol/l urea
(62). The alpha subunit of hCG is virtually identical to the alpha subunits of LH,
FSH and TSH and can be replaced by them (8,9,47,56,57,67). The beta subunit
is very similar to the beta subunit of LH but is hormone specific (8,47,56,57).
The alpha subunit consists of 92 amino acids with 5 disulphide branches it has a
molecular weight of 14,500 daltons and has two branched-chain carbohydrate
groups attached via N-asparagine linkages at positions 52 and 78. The beta
subunit consists of 145 amino acids with 6 disulphide bridges (9,47,56,57) it
has a molecular weight of 22,200 daltons and two branched-chain carbohydrate
groups are attached via N-asparagine linkages at position 13 and 30 (60). The
major difference between the beta subunit of hCG and that of the other
glycoprotein hormones is that hCG has a unique 30 amino acid 'tailpiece' known
as the carboxyterminal peptide (CTP) (47,56,57) which has 4 linear carbohydrate
groups attached via O-serine linkages at positions 121, 127, 132 and 138 (61).
The free subunits retain immunological activity but have negligible biological
activity (17,52,67). Separated subunits spontaneously recombine (17,57,62),
with concomitant recovery of biological activity, when incubated at weakly acidic
or alkaline pH. The carbohydrate attachments are not involved in the
immunological reactions of hCG, but are required for full biological activity, as
shown by bioassay assay studies using desialylated and deglycosylated
hCG(64,65,66,68).
The biological and immunological properties or nLu are resistant to snort
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incubation with trypsin and can withstand pH changes over the pH range 3- 11,
but heat quickly denatures the protein, with resultant loss of biological and
immunological activity (68).
The properties of hCG and its subunits are summarised in Table 1. The amino
acid sequence of the beta subunit of hCG and the structure of the carbohydrate
groups are presented in Figures 1 a) and b).
2.1.b. Immunochemistry of hCG
Purified hCG, hCG beta subunit and enzymatically cleaved or chemically
synthesised CTP have been used as immunogens in attempts to produce sensitive
and specific antisera. The beta subunits of hCG and LH are very similar
( Figure 2) and most antisera to the hCG beta subunit which do not involve the
hCG-unique CTP will cross react with LH (8,17,52,63,67,69,70,71,72).
Both conformational and linear antigenic determinants are present on the hCG beta
subunit. Antisera against conformational determinants which are masked when
the alpha and beta subunits are joined may be highly specific but measure only the
biologically inactive free beta subunits. Antisera against beta conformational
determinants which are exposed in the dimer hCG molecule measure total (ie, free
plus dimer) hCG, but LH may cross react( SB6 antiserum of Vaitukaitis, 1974)
(69).
Antisera raised to conformational determinants involving both the alpha and beta
subunits are not specific for hCG, as LH reacts equally well, however, free
subunits are not detected (H80 antiserum of Chen, 1980) (70).
The unique 30 amino acid CTP of the hCG beta subunit contains a linear antigenic
determinant, and antisera raised against this are completely specific for hCG.
However, this type of antiserum has low sensitivity and suffers from a
non-specific protein effect (H93 antiserum of Chen, 1980) (52,70).
Birken and Canfield (47) have confirmed that the CTP is not involved in the
conformational determinants of the 'core' area of the beta subunit. S waminathan
and Braunstein (72) propose two major conformational determinants involving
amino acid residues 21- 31 with a disulphide bridge between cysteine residues 23
or 26 and 72 or 110, and amino acid residues 21- 34 linked to residues 65- 71.
Chen et al (70) propose that the primary linear antigenic determinant of the CTP
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Table 1
Properties of hCG and its subunits
hCG dimer alpha beta
Molecular weight 36,700 14,500 22,200
Carbohydrate 30 29 32
28 6Number of CHO groups
237 145Number of amino acids 92
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Figure 1
a) The amino acid sequence of the beta subunit of hCG
b) the structure of its carbohydrate attachments
(from Birken and Canfield, 1977 (47)
and Kessler, 1980 (60,61))
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involves the two end residues (Pro-Gin) in co-operation with residues 133- 136
(Arg-Leu-Pro-Gly).
2.1.c. Receptor Bindin and Mechanism of Action of hCG
hCG receptors (hCG/LH receptors) are found in the ovaries and testes and are of
two types:
a) high capacity, low affinity
b) low capacity, high affinity
The receptors bind hCG and the almost identical LH, but hCG has a two-to-five
fold greater affinity for the receptor (8,69,73).
Free alpha and beta subunits appear to be recognised by the receptor, but the free
beta subunit has been reported to have negligible biological activity (0.1% or less
that of dimer hCG) (17,52,67,73).
It has been suggested that the hCG molecule has three receptor binding sites, two
on the alpha subunit and one on the beta subunit, and that correct conformation of
all three is necessary for full hormone action, ie receptor binding and cellular
response. The alpha binding sites may not be specific for hCG as other
glycoprotein hormones have almost identical alpha subunits, but the beta binding
site would be hormone specific (8,17,52,57).
A 'beta determinant loop' theory has been proposed by Moore et at (74) in which
the beta subunit residues Cys 93- Cys 100 form a loop within which there is an
overall negative, positive or neutral charge depending upon the amino acid content
of the loop. Those hormones with luteinising activity have a net neutral or
positive charge within the loop, while FSH and TSH have a net negative charge
( Figure 3 )(74,75).
The hCG/LH receptor is located on the cell membrane and consists of two
functional subunits, the hormone binding subunit and the adenylate cyclase
associated catalytic subunit (8,57,75). These subunits are structurally
independent and are coupled by guanylyl nucleotide binding protein (G-protein)
during hormone binding and catalytic activation.
hCG hindinc by cell receptors leads to intracellular response via adenylate
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Figure 2
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Figure 3
The 'beta- determinant loops' of hCG, LH, FSH and TSH
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cyclase activation and accumulation of cAMP. cAMP, the 'second messenger', is
bound to a regulatory protein kinase subunit causing activation of the catalytic
subunit of the receptor the activated catalytic subunit causes phosphorylation of
specific( but as yet unknown) intracellular protein(s) which leads to
steroidogenesis by acceleration of the conversion of cholesterol to
pregnenolone( Figure 4) (8,57,75).
hCG binding to receptors in vitro is not inhibited by desialylation or by
deglycosylation. However, deglycosylated hCG fails to induce steroidogenesis,
implying that sugar residues internal to sialic acid are required for full hormone
action (17,65,66,68,75).
A synthetic fragment of the same amino acid sequence as residues 39 -71 of the
hCG beta subunit has been shown (52) to have some slight biological activity,
and it has been proposed that this area contains the amino acid residues required
for receptor recognition and cellular response. It is of interest that the beta
subunits of hCG and LH are identical in this section except for a single amino acid
substitution at position 58 (Asn/hCG, Thr/LH).
It has been reported that antibodies to the 30 amino acid CTP do not block receptor
binding or inhibit cellular response of hCG in vivo (52), but this may be due to
dissociation of the loosely bound circulating antibody-hCG complex (70). The
role of the CTP in the production and action of hCG remains unclear.
2.1.d. Purification and Measurement of hCG
hCG can be extracted from urine using various non-specific protein
extraction/precipitation methods such as ammonium sulphate precipitation, acetone
precipitation, kaolin extraction, butanol/toluene extraction. These crude
extractions can then be followed by various chromatographic techniques to isolate
hCG from other proteins and glycoprotein hormones
(45-51,54,55,58,59,76,77,78). The physico-chemical characteristics which may
be used in purifying hCG from a crude urine protein extract include size, charge,
lectin affinity and isoelectric point.
Size
The large amount of carbohydrate in hCG (30%) results in a large 5toke's racuus
of the molecule. In gel filtration studies (45,67), hCG elutes in the area of
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molecular weight 70,000 daltons, even though the actual molecular weight is
36,700. The other glycoprotein hormones, LH, FSH and TSH are smaller (57)
and have less carbohydrate and so have a greater elution volume than hCG.
Charge
hCG can be separated from other proteins using ion-exchange chromatography
(51,58). The isoelectric point of biologically active hCG is 4.2: above this pH
hCG is in the anionic form and can be separated from cations or uncharged
molecules using DEAE-cellulose, an anion exchanger.
Lectin Affinity
hCG binds to the lectins Concanavilin A( from jack beans) and lentil lectin (79).
These lectins are group specific adsorbants of terminal alpha-D glucopyranosyl
and alpha-D mannopyranosyl residues. Elution of adsorbed hCG( and other
adsorbed glycoproteins) is usually performed using alpha-D methylmannoside.
Isoelectric Point
hCG may be separated from some other proteins using isoelectric focusing
(19,53,55), however, as the sample volume used is usually very small, this
technique is used mainly to assess the purity of a protein preparation rather than as
a purification method per se.
Measurement of hCG
Immunological and biological methods are available for the measurement of hCG
(8,9,44,46,65,69,73,77-100). If the purification processes used isolate and purify
only dimer hCG then the immunological and biological activities of the purified
hCG should increase in parallel. However, if hCG is degraded to it subunits or
deglycosylated during the process, or if inactive fragments are lost, the
biological/immunological ratio will change (65,80,82).
Immunological methods of measurement vary in sensitivity and specificity and
range in sophistication from do-it-yourself pregnancy tests using a modified
haem-agglutination inhibition method and non-specific antisera, to highly sensitive
radio- and enzyme linked- immunoassays and immunometric assays which
employ specific antisera and can detect less than 1 IU/1 hCG
(9,69,71,73,78,80,82-93,97).
Immunoassays using antisera to intact hCG may measure hCG and LH equally
well. Those using anti-hCG beta, for example the SB6 antiserum of Vaitukaitis,
are more specific (69), but there may be significant cross-reaction with LH. More
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specific immunoassays use two antibodies, eg anti-hCG beta and anti-hCG (H80
type) or anti-CTP (H93 type). Immunometric methods appear to be more
sensitive and specific than radioimmunoassay methods, and results can be
obtained in a few minutes as opposed to several hours (87,96).
Biological methods (8,9,57,73,77,80,81,82,100) of measuring the luteinising
activity of hCG date from the Aschheim Zondeck test of 1927 (100) in which
immature female mice were injected with patients' urine and the ovaries then
examined for hyperaemia and luteinisation, the biological response to hCG. Other
early pregnancy-testing biological assays used male frogs and toads, which
responded to injection of hCG-containing urine by discharge of sperm. This type
of pregnancy test has been superceded by immunological methods (86).
Bioassays currently used are designed to test a) the LH effect or b) the FSH effect
of hCG by measuring:
a) increased weight of the ventral prostate of immature male rats or testosterone
production by leyd.ig cells from rat testes
b) rate of ovarian weight gain or ovarian ascorbic acid depletion in
hypophysectomised female rats
Immunological and biological testing have been combined in the development of a
very sensitive radioreceptor test (8,84,85). The receptor, isolated from ovaries or
testes, acts as the binder. LH also binds, but hCG has a greater affinity for the
receptor and so LH interference is negligible unless it is present in high
concentrations. Free alpha and beta subunits and other glycoprotein hormones do
not bind and so are not measured. The sensitivity of the test is about 5 IU/l and
the results can be obtained after one hour, making this a useful test when speedy
confirmation of very early pregnancy is required.
Standardisation of hCG Assays
Three types of material may be used in standardising an hCG assay (94,95,96):
1 The Second International Standard of Human Chorionic Gonadotropin for
Bioassay( 2nd IS hCG, 1964)
2 The International Reference Preparation of hCG for Immunoassay
( IRP, 1974)
22The thyrotropic activity of hCG in women with hyperemesis Qravidarum
3 The International Reference Preparation of the Beta Subunit of hCG for
Immunoassay (IRP beta subunit, 1974)
The 2nd IS is a relatively impure preparation, while the IRP hCG and IRP hCG
beta subunit preparations are highly purified and homogenous and have been
recommended by the WHO Expert Committee on Biological Standards for use in
standardisation of hCG and hCG beta subunit measurements by immunological
methods. The 2nd IS is not recommended for immunoassay standardisation, and
use of this heterogenous preparation may lead to over- or under-estimation of hCG
when antisera which are not specific for intact hCG are employed (96).
2.1.e. hCG Production, Function and Metabolism in Normal and
Abnormal Pregnancy
hCG may be produced in small amounts by the pituitary of all normal adults (12),
but plasma levels are measurable only by ultra-sensitive and specific immunoassay
techniques. By routine laboratory methods of hCG measurement hCG is
undetectable in the blood and urine of all normal males and non-pregnant females
(9,56).
hCG is produced by the trophoblastic tissue of the placenta (8,9,56,99,101) and
maternal serum levels of the hormone rise dramatically after conception, roughly
doubling every two days, and peak levels of up to 100,000 IU/I or more are
reached at 40-90 days gestation. Serum hCG levels then fall to a plateau value of
approximately 1/10th that reached during peak production, and remain at this level
until term (3,56,76,102) (Figure 5).
Alpha and beta subunit production rates are not equal: beta synthesis is initially
greater, leading to the presence of free beta subunits in the serum. The rate of
alpha subunit production increases to match and then overtake that of the beta
subunit, so that in later pregnancy very little free beta will be found in the serum,
whereas the level of free alpha subunit increases until term (9,56,102,103,104).
Alpha and beta subunits are translated from separate mRNA's under separate
control mechanisms. Both subunits are synthesised as precursors, the alpha
subunit in the cytotrophoblastic cells and the beta subunit in the
syncyti otrophoblas tic cells of the developing placenta.Dimer hCG, after precursor
cleavage, carbohydrate attachment and non-covalent binding of the subunits, is
secreted from the synciotrophoblastic cells into the maternal and foetal blood(56).
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Figure 5
Serum hCG levels during pregnancy
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Control of hCG secretion is unclear, but is thought to involve rate-limiting
production of one of the subunits (9.56.99.101.103.104)_
The half-life of hCG in the blood plasma is 12-36 hours (9). The half-lives of the
subunits are considerably shorter, 6 minutes and 11 minutes for the alpha and beta
subunit respectively. The renal clearance rates of hCG and its alpha and beta
subunits are approximately 1.0, 0.2 and 0.2 ml/minute and the metabolic clearance
rates are 2.1, 85 and 32 ml/minute respectively (63). Renal clearance accounts
for less than 30% of hCG disposal and a negligible amount of subunit disposal,
however non-renal clearance pathways are not clear. It is known that desialylated
hCG is rapidly cleared from plasma by hepatic uptake (47,59,64,), but it is not
known if peripheral desialylation is a significant step in the catabolism of hCG
(105). A beta subunit fragment has been found in urine (106) and identified as an
hCG degradation product, but this is normally found in small amounts. Large
amounts of a beta-core fragment have recently been found in urine (107), and this
may be a major form of urinary hCG.
hCG stimulates steroidogenesis in the leydig cells of the testes and ovarian luteal
cells (56,57,73). The function of hCG in the female is to maintain the corpus
luteum and to stimulate progesterone secretion by the luteinised cells.
Progesterone is required for support of the endometrium during and after
implantation of the blastocyst. hCG may also be involved in inhibiting ovulation
during pregnancy and there is evidence to suggest that hCG plays a role in the
sexual development of the male foetus by stimulating testosterone secretion by the
foetal testes (8). In addition, it has been proposed that hCG in some way acts as
an immunosuppressive agent, masking foetal antigens and thus preventing
maternal immunorejection of the foetus (8).
Around 6- 8 weeks after conception, the placenta becomes the major site of
progesterone synthesis. The corpus luteum, which remains until term, is
apparently no longer needed for this purpose (8,9). In ectopic pregnancies and
pregnancies ending in early, spontaneous abortion, hCG levels are lower than
normal (84,85), while significantly higher levels of hCG are found in multiple
pregnancies than in singleton pregnancies (102,108).
Very high levels of hCG are also found in gestational trophoblastic disease
(45-50,56,109,110), which can be benign (hydatidiform mole/ molar pregnancy)
or malignant (choriocarcinoma )(111). In the benign form there is proliferation of
the trophoblast, but no embryo. hCG production is high, nausea and vomiting are
common, the uterus is enlarged for dates and the patient usually presents with
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vaginal bleeding (111). Choriocarcinoma is a highly invasive malignant condition
usually arising from embryonic or gonadal tissue. hCG production may be
extremely high and serial measurements of hCG during and after treatment are
useful in monitoring the success of the treatment and detecting recurrence of the
disease (8,9,56,82,109, 110).
hCG production in gestational trophoblastic disease is usually much higher than in
normal pregnancy (8,56,109), and there may also be excessive production of one
or both subunits, eg, at 10- 18 weeks gestation the ratio of beta subunit to hCG
dimer has been reported to be 3.7 in molar pregnancy compared to the normal
pregnancy ratio of 1.8 (8). The hCG produced in choriocarcinoma may have
variable amounts of carbohydrate and low biological activity, but immunological
activity is retained (45,46,48-54,59).
hCG production in women with pregnancy-associated vomiting and hyperemesis
gravidarum have been studied, but conflicting results have been obtained. One
study (112) showed significantly higher serum hCG levels in women with early
pregnancy vomiting than in women without 'morning sickness', but another (5)
found lower urinary hCG levels in women with hyperemesis gravidarum than in
normal pregnant women. A study (6) of 42 women with hyperemesis gravidarum
found significantly higher serum hCG levels at 7- 14 weeks gestation when
compared to 115 normal pregnant women, but a more recent study (113) of 35
women with hyperemesis gravidarum found no significant difference in serum
hCG levels when compared to non-vomiting pregnant women.
The reasons for this non-agreement in similar studies is unclear, but hCG remains
a suspected causal factor in the development of hyperemesis gravidarum for three
main reasons:
1. production of hCG is highest when nausea and vomiting are most severe
(1,2,3,100,101)
2. nausea and vomiting are found in gestational trophoblastic disease and this is
also associated with high hCG production (9,108,109)
3. women with multiple pregnancy suffer more nausea and vomiting than women
with singleton pregnancy: these women also have higher hCG levels(102,107).
2.1.f. The Intrinsic Thyrotropic Activity of hCG
The chemical structure of hCG is very similar to that of TSH (56,57,114) and
conditions associated with very high hCG production have also been shown to be
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associated with thyroid hyperfunction (22,25,26,28-40). Because of this
similarity of structure and apparent hCG-associated thyrotoxicosis, various
preparations of hCG have been tested for thyrotropic activity (13-21,115,122).
These preparations have included extracts of serum and urine of pregnant women,
highly purified and recombinant hCG and purified alpha and beta subunits.
The bioassay most commonly used to measure thyrotropic activity in the past has
been the McKenzie mouse bioassay (123), in which radioactive iodine is
administered and blood levels of radioactivity measured at 2, 9 and 22 hours after
injection of the material being tested. A chick bioassay has also been used (121),
but showed low sensitivity, and more recent tests have employed bovine (16),
porcine (19) and human (15,19,117,118) thyroid tissue bioassays and a rat
thyroid cell line (FRTL-5) bioassay (20,21).
Nisula and co-workers have consistently reported thyrotropic activity in hCG
preparations when tested using the mouse bioassay and measurement of adenylate
cyclase activity in human thyroid plasma membranes (13,14,17,18,120). The
thyrotropic activity and primary hCG activity (luteinising activity) increasing in
parallel during purification of hCG, implying that it is hCG itself which is the
thyrotropic agent.
Amir et al (16) found little, if any, thyrotropic activity in crude and purified hCG
preparation using bovine thyroid membranes, but reported significant binding of
asialo-hCG to thyroid receptors (117): this could explain Amir's finding that
crude hCG appeared to have a greater affinity for thyroid receptors than highly
purified hCG (16).
Kenimer et al could not separate the thyrotropic and luteinising activities of hCG
extracted from the urine of a woman with hydatidiform mole, concluding that the
thyrotropin in hydatidiform moles is human chorionic gonadotropin (115).
Uchimura et al tested the thyrotropic activity of highly purified hCG using the
mouse bioassay and cAMP response in human thyroid slices. Definite thyrotropic
activity in hCG was found in the mouse bioassay whereas the results obtained
with human tissue were inconclusive due to large between assay variation (15).
Carayon et al (18) found that both purified and crude hCG stimulated cAMP
production in human thyroid tissue in vitro. Studies investigating the thyrotropic
activity of hCG have found that the thyrotropic activity co-purifies with and cannot
be separated from hCG (7,14). When hCG was separated by isoelectric focusing
and the separate fractions tested, the more acidic fractions appeared to have greater
thyrotropic activity (19,20).
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Silverberg et al (118) tested the ability of a commercial hCG preparation to
displace radioactive TSH from receptors on human thyroid membranes and to
generate cAMP in human thyroid slices. Positive responses were found at very
high doses (40,000 U/1) of hCG. Commercially produced, partially purified
hCG administered in one large dose to normal men produced increased thyroidal
release of iodine (119), but the response was much weaker and slower than that
induced by TSH or TRH, and there was no significant change in blood levels of
T4, T3 and TSH after 48 hours.
Dissociation of the dimer into separate alpha and beta subunits followed by
purification and recombination failed to eliminate the thyrotropic activity associated
with hCG (17). The thyrotropic activity found is weak: comparative potency
ratios of 2,000- 42,000 units of hCG per milliunit of TSH have been reported
using various in vivo and in vitro studies and different preparations of hCG and
TSH (18,19,21,115), but this weak thyrotropic activity could become significant
when hCG concentrations in serum reach the very high levels commonly found in
early pregnancy and gestational trophoblastic disease.
In.addition to these direct methods of assessing thyrotropic activity, hCG has
been implicated as a thyroid stimulator by results of studies into TSH levels in
pregnancy (124,125,126). These studies found that TSH levels were lowest at
the time of peak hCG production. One study (125) reported a mirroring of
bioassayable TSH and hCG levels and an apparent inverse relationship between
serum hCG and TSH levels, implying that hCG is a thyrotropic agent (Figure 6).
If hCG has thyrotropic activity due to its structural similarity to TSH, then it is
perhaps to be expected that LH, the structure of which is almost identical to that of
hCG, would also have thyrotropic activity. A study of the thyrotropic activity of
LH demonstrated that it is a potent inhibitor of TSH binding to bovine receptors
and that it causes significant cAMP generation in human thyroid slices (18}.
The thyrotropic activity of LH was reported to be more than 150 times that of
hCG( unit for unit) (18). The major difference in the structures of these two
hormones is the presence on the hCG beta subunit of the 30 amino acid CTP.
When hCG was stripped of this tailpiece the thyrotropic activity almost tripled
(119), and it has been speculated that hCG is the luteinising hormone of
pregnancy in order to avoid high levels of LH, which would lead to invariable
pregnancy- associated thyrotoxicosis because of the significantly higher
thyrotropic activity of LH (18).
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Figure 6
Comparison of hCG, TSH and bioassayable TSH in the
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This theory is supported by the recent report of two cases of clinical thyrotoxicosis
suddenly developing in women being treated for infertility (127). In one case LH
and FSH only were administered, and the patient's free thyroid hormone levels
approximately doubled. In the other case 1,000 units of hCG were also given,
and the patient's free thyroid hormone levels increased more than five times. It
could be postulated that the thyroid was stimulated in both cases by the exogenous
LH, but that the response was augmented in the second patient by the additional
large bolus of hCG.
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2.2. Hyperemesis Gravidarum
Nausea and vomiting occur in over 50% of normal pregnancies and are accepted
normal symptoms of early pregnancy (1,2). This normal emesis gravidarum can,
however, become severe and frequent enough to cause disturbed nutrition and lead
to metabolic imbalance- hyperemesis gravidarum.
Hyperemesis gravidarum is characterised by severe, intractable vomiting, with
ketonuria and significant weight loss. The majority of patients present for the first
time between 8 and 12 weeks gestation. The symptoms usually recede as the
pregnancy advances, but some patients continue to suffer through the second
trimester, requiring several re-admissions for in-patient treatment (1,2,128,129).
Upon admission the patient may be severely dehydrated and correction of fluid
and electrolyte imbalance is urgently required, however other causes of vomiting,
eg urinary tract infection, appendicitis, hepatitis, thyrotoxicosis, should be
excluded before a diagnosis of hyperemesis gravidarum is confirmed (1,2,128).
2.2.a. Aetiology of hyperemesis gravidarum
The aetiology of hyperemesis gravidarum, although investigated for many years,
is still unknown. The condition itself has been recognised since 2000 B.C., and
suggested aetiological factors over the years have included vitamin B deficiency,
allergy to secretions of the corpus luteum, increased sensitivity to histamine,
hypopituitarism, hypoadrenalism, sensitivity to hCG or oestrogen, the sex of the
foetus- male then female being proposed- and psychosomatic (1,2,113-134).
In his excellent review of the syndrome of nausea and vomiting of pregnancy,
Fairweather (1) presents a comprehensive survey of various aspects of
hyperemesis gravidarum and divides the numerous aetiological theories into four
groups:-
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Neurotic or Psychosomatic
Results of psychological and personality tests of patients with hyperemesis
gravidarum have shown no general agreement, but a psychosomatic factor is still
strongly suspected by some (1,2,129,134). The psychosomatic theory is
supported by the fact that many patients with hyperemesis gravidarum stop
vomiting when admitted to hospital, but before any treatment has been given. In
addition, placebo treatment has often been effective in improving symptoms, as
has the administration of ACTH, used in treating hyperemesis gravidarum for
more than twenty years but shown by Ylikorkala et al to have no specific
therapeutic effect (131). However, this alleviation of symptoms in the expectation
of medical attention is not limited to hyperemesis gravidarum and is not
demonstrated in the majority of cases. Personality testing of women suffering
from hyperemesis gravidarum may indeed reveal a clearly marked association
with hysterical personality, immaturity and strong mother dependence (1),
but personality testing of a wretchedly sick, pregnant woman in an alien
environment may not be valid when compared to healthy asymptomatic pregnant
women, and so, while psychological factors may contribute to the development of
hyperemesis gravidarum, the search has continued for a more physiological
primary cause.
Allergic
Allergy theories have implicated histamine, secretions of the corpus luteum,
antigenicity of the foetus, hCG and isoagglutinins, but these theories have not
been fully explained or tested and so remain speculative. Anti-histamines have
been used as anti-emetics in hyperemesis gravidarum (1,2,113,130), but the
success of this type of therapy could be due to their sedative effect and/or to the
psychological effect of the treatment on the patient.
Metabolic
Suggested metabolic causes of hyperemesis gravidarum have included liver
glycogen deficiency, vitamin B deficiency and production of intestinal toxins (1).
However, there have been no new metabolic theories for many years and it is now
generally accepted that the changes in metabolism seen in hyperemesis gravidarum
are a consequence of the condition rather than a cause.
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Endocrine
Pregnancy is associated with many pronounced hormonal changes and so an
endocrine cause of hyperemesis gravidarum has been investigated. Suggested
endocrine factors have included hypopituitarism, hypoadrenalism, increased
oestrogen, progesterone and hCG more recently, beta lipotropin hormone has
been named as a possible aetiological factor (1,2,7,10,113,129,130,132).
Kauppila et al (132) found no hypofunction of the anterior pituitary or of the
adrenal cortex in nine women with hyperemesis gravidarum. ACTH levels were
found to be higher in hyperemesis gravidarum than in normal pregnancy in this
study but this may have been related to stress imposed by the condition.
Oestradiol and progesterone were not found to be significantly different between
women suffering from early pregnancy nausea and vomiting and asymptomatic
women (7,10), although a more recent study (113) showed elevated oestrogen
levels in women with hyperemesis gravidarum. 17-alpha-hydroxyprogesterone
was not found to be significantly different between vomiting and non-vomiting
women (7) the beta lipotropin theory (130) has not been tested to date.
hCG has been regarded as a prime candidate for playing a causal role in the
development of hyperemesis gravidarum because of the following established
relationships:
production of hCG is highest when nausea and vomiting are most common
and severe, and there is an almost exact mirroring of the time of peak hCG
production and gestational age at which hyperemesis develops (Figure 7)
(1,2,3,102).
nausea and vomiting may be found in hydatidiform mole and
choriocarcinoma, both of which are associated with high hCG levels
(8.9.38.109.110.
women with multiple pregnancy suffer more nausea and vomiting than
women with singleton pregnancy these women also have higher hCG levels
(1,2,102,108).
There have been several studies of hCG levels in emesis and hyperemesis
gravidarum, but the results have been conflicting. Schoeneck presented evidence
to show increased urinary gonadotropin in patients with nausea and vomiting in
early nregnancv when compared to asymptomatic pregnant women (4), but
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Figure 7
Comparison of hCG production pattern and gestational
age at presentation with hyperemesis gravidarum
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Fairweather and Lorraine disputed this and reported lower hCG excretion at 7-15
weeks gestation in 90 women with hyperemesis gravidarum as compared to that
in 20 normal pregnant women (5). Soules measured serum hCG in 5 patients
with hyperemesis gravidarum and found higher levels in 2 and normal levels in 3
(7), when compared to asymptomatic women. Kaupilla et al found significantly
higher serum hCG levels in 38 women with hyperemesis gravidarum at 7- 14
weeks gestation compared to 102 normal women of the same gestational age (6)
but no difference in hCG levels at 15-20 weeks. In a separate study (112),
Kaupilla measured serum hCG levels in pregnant women with daily vomiting and
compared these with hCG levels in completely asymptomatic pregnant women,
reporting significantly higher hCG levels in the vomiting women. These results
agree with those of Masson and Chau (10) who found significantly higher serum
levels in women with nausea and vomiting of early pregnancy when compared to
asymptomatic women of the same gestational age, but conflict with those of
Soules (7), who found no obvious correlation between serum hCG and the
incidence or severity of nausea and vomiting in early pregnancy. A more recent
study (113) has also failed to establish higher than normal hCG levels in
hyperemesis gravidarum, marginally lower serum levels in fact being found.
The reason for this non-agreement between apparently similar studies is not clear,
but methodological differences undoubtedly contribute. This is particularly true
for the early studies of hCG excretion, where different bioassays were used.to
measure hCG activity in urine. Urine may contain varying amounts of
biologically inactive fragments (8,106,107) and may be susceptible to
desialylation( and therefore biological inactivation (65,68)) by bacterial
neuraminidase. Serum hCG results, which were obtained by radioimmunoassay,
are probably more comparable, but there is no standardised procedure for assay or
calibration and significant inter-method variation does occur (83,89,96).
2.2.b. Incidence of hyperemesis gravidarum
Reported incidence rates of hyperemesis gravidarum vary from almost zero to over
10 per 1,000 births (133), but this variation probably reflects differences in
reporting methods and diagnostic criteriae used than true variation.
Fairweather, in his comprehensive review (1), gives an estimated overall incidence
rate of approximately 3 per 1,000 births. Fitzgerald found a rate of 6- 10 per
1,000 births in North East Scotland between the two World wars, but significantly
lower rates during both Wars the incidence rate had returned to its pre-World
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War II rate by 1949 (129
Incidence in Oriental countries has been reported to be lower than in the West (1),
but a recent study in Hong Kong reported an incidence rate of 5.36 per 1,000
births (11).
No obvious relationship has been found between hyperemesis gravidarum and
race, colour, marital status, financial position or circumstances of the pregnancy,
however, the condition seems to be more common in primigravidas and has been
reported to occur more frequently in women with multiple pregnancies
(1,2,113,133).
2.2.c. Consequencies of hyperemesis gravidarum
i) Maternal debilitation and mortality
ii) Pregnancy outcome
i) Maternal debilitation and mortality
Prolonged severe vomiting leads to nutritional deficiencies, dehydration, alkalosis
and potassium depletion (1,127,128) Brain stem lesions similar to those found in
Wernicke's encephalopathy may develop dehydration may lead to renal failure,
and nutritional protein and carbohydrate deficiency may lead to fatty infiltration of
the liver. Degenerative neuritis of the peripheral nerves and retinal haemorrhages
may also be found.
Women presenting with hyperemesis gravidarum may be very ill, but death from
this condition is now almost unknown in developed countries. The condition
itself is no better understood, but its effects on metabolism with regard to fluid and
electrolyte imbalance are now well known and can be effectively assessed,
monitored and treated. Mortality figures in UK in the period 1931- 1940 were
159 per million births by 1960 the mortality rate had dropped to 3 per million
births (129), undoubtedly because of the increased awareness of the dangerous
likelihood of hypokalaemia in these women and in improved, timely treatment
(1,2,113,128,129).
Hyperemesis gravidarum is therefore no longer a life threatening condition,
provided correct supportive therapy is given. Nevertheless, the professional life
of the women is disrupted, the home life of the family disturbed, and there may be
understandably ambivalent feelings toward the pregnancy, some women
36The thyrotropic activity of hCG in women with hyperemesis aravidarum
requesting termination
ii) Pregnancy outcome
The occurrence of hyperemesis gravidarum- has been reported to have no effect on
pregnancy outcome with regard to birthweight, APGAR scores, incidence of
congenital deformities, stillbirth or abortion (1,135). Two recent studies,
however, have reported higher than expected numbers of babies with congenital
abnormalities, notably Down Syndrome and central nervous system
malformations (113,133). These studies also showed a reduced risk of foetal loss
associated with hyperemesis gravidarum and an apparent preponderance of female
babies born to women with hvoeremesis 2ravidarum.
2.2.d. Occurrence of hyperemesis gravidarum or abortion in
previous and subsequent pregnancies
Women with hyperemesis gravidarum are likely to have had the condition in a
previous pregnancy and/or to develop the condition again in subsequent
pregnancies. Fitzgerald found (129) that of 56 women with hyperemesis in their
first pregnancy, 27 (48%) were affected in their second pregnancy and that of
106 women with hyperemesis in their second pregnancy, 50 (47%) had also had
the condition in their first pregnancy of 82 women with hyperemesis in their third
pregnancy, 44 (54%) had had the condition in both previous pregnancies and 11
(13%) had had hyperemesis in one of their previous pregnancies. Fairweather
(1,2) found that 27% of his multigravidae patients with hyperemesis had also had
the condition in a previous pregnancy. Hyperemesis gravidarum therefore
commonly, but not invariably, recurs in subsequent pregnancies, and may occur
in a multigravida with no previous history of hyperemesis.
Fairweather (1,2) also found a higher than normal incidence of abortion in
previous pregnancies in women with hyperemesis gravidarum, reporting 41% and
37% in two studies, compared with 14% in the control population. Bouillon, in a
study of 33 hyperemesis gravidarum patients (135), found an abortion rate in
previous pregnancies of 33%. The significance of this relationship is unknown,
but it has been reported (136) that women with no nausea or vomiting in early
pregancy are more likely to abort than those who suffer from morning sickness. It
may be postulated that whatever causes the nausea is also in some way acting as
an 'pregnancy protecting' or anti-abortion agent.
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2.2.e. Treatment of hyperemesis gravidarum
Since the cause of hyperemesis gravidarum is not known, the treatment regimes
have tended to be as varied and unrelated as the aetiological theories. Fairweather
lists 30 therapeutic measures employed since 1940, and these range from ACTH
injections to inductive current therapy, vitamin B 12 treatment, administration of
serum from a normal pregnant woman and intravenous honey (1). Treatment by
behavioural intervention has also been used, with reported success (134).
Drugs administered in present-day treatment regimes include anti-histamines,
sedatives and phenothiazine anti-emetics. However, due to the potential danger of
drug taking in early pregnancy, some clinicians use no drugs, treatment being
based solely on i.v. supportive therapy after restoration of fluid and electrolyte
balance, and counselling.
A full general examination, routine blood chemistries and urine culture and
microscopy should be performed to rule out other possible causes of the vomiting.
Recovery is monitored by assessing weight gain patients discharged before
appreciable weight gain has been recorded are more likely to require readmission
for further treatment (1,2).
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2.3. Thyroid Function in Normal and Abnormal
Pregnancy
2.3.a. Thyroid function during normal pregnant}
During normal pregnancy there is an increase in the basal metabolic rate, thyroid
size, thyroidal turnover of iodide and thyroxine binding globulin( TBG). Both
the binding capacity and total concentration of TBG are increased, and this leads to
increased total thyroxine (T4) and triodothyronine (T3) in serum (137-149),
although serum T4 levels rise and plateau earlier than would be expected if the
change was due to TBG alone (145,146,149) Renal clearance of iodine is
increased during pregnancy and this is associated with a decrease in the plasma
iodine concentration (137). This in turn leads to a compensatory increase in
thyroidal clearance of iodine which may result in goitre (138,142-144)
pregnancy-associated goitre is very common in areas of low iodine intake, one
study reporting an incidence of 74% (143).
Serum concentrations of the physiologically active thyroid hormones free T4 and
free T3 during normal pregnancy have been reported to be unchanged
(24,142,147) or slightly increased (125,147-149) during the first trimester and
unchanged or slightly decreased in the second and third trimesters.
(125,145-151). The apparent decrease in free T4 in late pregnancy has been
suspected to be an artefactual finding caused by a 'low albumin effect' when using
T4 analogue kits (142,151-153). Albumin concentrations in serum have been
found to be 16% lower in late pregnancy than in early pregnancy (152). When
measuring free thyroid hormones by radioimmunoassay, serum albumin is
assumed to bind some of the tracer. When less albumin is present, as in advanced
pregnancy, less tracer is bound and so more tracer is available to compete with the
patient's free T4 for binding sites on the antibody. Antibody binding of tracer is
inversely proportional to the patient's free T4 concentration, and so low albumin
concentrations could lead to spuriously low free T4 results being obtained. When
free T4 and free T3 in the first, second and third trimesters were measured
(146,152), free T4 and free T3 were both reported to be significantly lower in. th
third trimester than in early pregnancy, but the difference appeared to be
exaggerated when an analogue method was used (152). These results supported
the findings of an earlier longitudinal study (149) which found a decrease in the
concentrations of free thyroid hormones in the third trimester when compared to
the first. This study also showed that free T4 in the first trimester was
significantly higher than the non-pregnant( +8 weeks post-partum) level (149).
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Taking the results of several cross-sectional and longitudinal studies collectively
(36,125,142,145-153), free T4 appears to increase in early pregnancy, then
decrease slightly but significantly in later pregnancy. Free T3 appears to be
unchanged initially, but significantly lower levels are found in the third trimester
( Figure 8). Whether free T4 normally increases above the upper limit of the
non-pregnant reference interval is still unclear. The degree of decrease in the
concentration of the free hormones in late pregnancy does not appear to cause
'abnormally' low levels unless an analogue method is used.
Thyroid stimulating hormone( TSH) levels in serum during normal pregnancy
have been reported to be similar to those in non-pregnant women (13 8,154), but
one study found a significant decrease in TSH levels at 2- 4 months gestation
(125), while another using an ultrasensitive TSH assay found that TSH levels in
the first trimester were considerably lower( 65%) than in the third trimester
(152). Three longitudinal studies of women with normal pregnancy also showed
lower TSH levels in the first trimester than in later pregnancy (125,146,149).
TSH response to TRH during pregnancy has been reported to be increased (23),
decreased (148,154) and unchanged (27,155).
Reverse T3 levels during pregnancy have been reported to be significantly higher
than in the non-pregnant state (138). The significance of this is not known, but it
may be accounted for by increased binding to TBG and/or increased peripheral
deiodination of T4.
Thyroid function indices measured during pregnancy may therefore be
significantly different from non-pregnant levels and the levels of the free
hormones and TSH may change significantly during pregnancy. The degree and
clinical significance, if any, of these changes is not known and, as there is no
generally accepted pregnancy-adjusted reference interval for thyroid function
indices, biochemical confirmation of suspected mild thyrotoxicosis developing
during pregnancy is difficult. Clinical diagnosis is complicated by the accepted
occurrance during pregnancy of heat intolerance, anxiety, bruit, goitre and tremor.
Post-partum thyroid dysfunction is not uncommon (156), and this may be a
continuance or consequence of pregnancy-associated thyroidal changes. The
recent introduction of ultra-sensitive TSH measurements may prove to be a useful
adjunct in assessing thyroid function during pregnancy and post-partum
145.157).
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Figure 8
Thyroid function indices during pregnancy
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2.3.b. Thyrotoxicosis in Normal and Abnormal Prec-nancv
True thyrotoxicosis in normal pregnancy is rare, with a reported incidence of
0.05% (24), but correct diagnosis and treatment is important since untreated
thyrotoxicosis is associated with increased foetal loss and low birth weight
(24.,27,141). Due to the many thyroidal changes found in normal pregnancy and
the common occurrence in normal pregnancy of many 'thyrotoxic-like' signs,
such as tremor, heat intolerance, anxiety and goitre (24,143), accurate diagnosis
of thyrotoxicosis occuring for the first time during pregnancy becomes difficult.
Moreover, in addition to 'true' thyrotoxicosis, there have been several reports
(22,25,26,28,29,36,135,155) of a transient pregnancy-associated thyrotoxicosis,
mild (hyperthyroxinaemia with no clinical symptoms) and severe (clinical
thyrotoxicosis) from which the patient may recover spontaneously as the
pregnancy advances or terminates. This transient pregnancy-associated
thyrotoxicosis does not appear to have a deleterious effect on the pregnancy,
although smaller birthweights have been reported in babies born to women with
hyperemesis gravidarum and hyperthyroxinaemia (135).
Thyrotoxicosis in gestational trophoblastic disease has been well documented
(30-38,116,121,142,162-166). The thyrotoxicosis may be of a mild, subclinical
type (biochemical thyrotoxicosis or euthyroid hyperthyroxinaemia)
(30,33,36,38,166-168) or overt (clinical thyrotoxicosis)(31,32,35,38). One
study of 11 women (30) with molar pregnancy revealed that in every case the
absolute thyroidal uptake of iodine was increased and that the sera of these patients
contained a thyrotropic agent distinct from TSH and hCT. After removal of the
mole this thyroid stimulator disappeared from the serum and the iodine metabolism
returned to normal. There have been reports of severe, life- threatening
thyrotoxicosis associated with hydatidiform mole and choriocarcinoma
(31,35,38), but most studies have shown that thyrotoxicosis in gestational
trophoblastic disease is usually biochemical rather than clinical and report
abnormal thyroid indices in 30-. 70% of patients with gestational trophoblastic
disease (32,34,38,166,167). The degree of thyrotoxicosis has been found to
correlate with the size of the mole or tumour (36-38), and thyroid function reverts
to normal very quickly after removal of the mole or successful treatment of the
choriocarcinoma. Subclinical and overt thyrotoxicosis are reported to be more
common in hydatidiform mole than in choriocarcinoma (31,34,37,116,166).
Thyrotoxicosis in hyperemesis gravidarum has been reported, but studies of
thyroid function in this condition are conflicting. Some authors have regarded the
hvneremesis as the presenting feature of true thyrotoxicosis (28,29), but it has
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been speculated that hyperemesis gravidarum is an expression of transient
pregnancy-associated hCG-induced thyrotoxicosis in these patients
(22,25,39,169,170).
In one study of 25 women with hyperemesis gravidarum, 40% were found to
have high free T4. levels, and these normalised when the hyperemesis resolved
(39). Another study (36) of 35 women with hyperemesis found significantly
higher protein bound iodine levels than in normal pregnant women matched for
gestational age, and 73% of women with hyperemesis gravidarum were found to
have higher total thyroxine and free thyroxine index results than normal pregnant
women of a similar duration of pregnancy (135). Serum reverse T3 has been
reported to be significantly higher in women with hyperemesis gravidarum than in
normal pregnant women (155).
A recent study in Hong Kong also found elevated thyroid function results in
hyperemesis gravidarum patients, almost 50% of whom had high T4 levels (40).
The total T4 increase in these women could not be accounted for by an increase in
TBG and correlated well with the free hormone levels, but the TSH levels in these
women were found to be normal. A separate study (170) showed that
hyperemetic women with hyperthyroxinaemia had significantly higher levels of
hCG in serum than hyperemetic pregnant women with normal T4 and reported
that, in agreement with others (116,148), hCG levels correlated with free T4
concentration in these patients.
The cause of this transient thyrotoxicosis or hyperthyroxinaemia of pregnancy is
as yet unknown. The placenta was for some time thought to produce a small
amount of a thyrotropic agent known as human chorionic thyrotropin (hCT)
(158-161). The thyroid stimulating activity of hCT was reported to be about 5-
10% that of pituitary TSH and the amount produced by the normal placenta
estimated to be about 5mIU, thus producing insignificant thyroid stimulation.
More recent work has failed to confirm the presence of hCT in serum or placental
tissue, however, and its existence is now doubtful. hCG, a hormone produced in
large amounts during normal pregnancy (3,8,9), has been found to exhibit weak
thyrotropic activity (13-21,118,119) and has been referred to as a 'placental
thyrotropin' (162). The significance of this property and the role of hCG in the
development of pregnancy-associated thyrotoxicosis is not yet clear, but transient
pregnancy-associated thyrotoxicosis consequently or coincidentally occurs at the
time of peak hCG production, ie, in early pregnancy (22,25,26,29).
Because of the considerable overlap in thyroid hormone levels and hCG
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concentrations in normal and hyperemetic pregnancy, and because of the lack of a
generally accepted reference interval for thyroid hormone levels during pregnancy,
causal and/or consequential relationships beween
hCG and hyperemesis gravidarum
hCG and thyrotoxicosis
thyrotoxicosis and hyperemesis gravidarum
are suspected but have yet to be established. A study (169) into thyroid function
and degree of sickness experienced during pregnancy found no correlation and,
while nausea and vomiting are found in more than 50% of normal pregnancies
(1,2,136) pregnancy-associated thyrotoxicosis is not commonly reported
(24,171). All pregnant women have high hCG levels, although the range of
concentration is wide,(3,8,9,102,170) and thyroid hormone levels, with the
exception of TSH (124,125,126,145-150), tend to parallel hCG levels
(25,124,125,149). However, hyperthyroxinaemia and thyrotoxicosis with
normal-for-dates hCG levels have been reported, and some patients with grossly
elevated hCG have normal T4 levels (33,135,172). Biological activity of hCG is
known to vary during gestation (80,81,82,101,103), and less active forms of
hCG, including excess free subunits, are produced in gestational trophoblastic
disease (53,81,98,110). Thyrotoxicosis or hyperthyroxinaemia developing in
conditions associated with high hCG production could be the result of a
combination of quantity and potency( biological activity) of hCG, rather than
more hCG per se, and it may be postulated that some pregnant women develop
hyperthyroxinaemia and/or thyrotoxicosis because they produce a more
thyrotropic form and/or more hCG than those who remain apparently euthyroid.
Variation in thyrotropic activity or potency of hCG could be due to structural
variation in the hCG molecule or an extended half-life, and these could be due to
amino acid substitution or differences in the degree of glycosylation, sialylation or
in the carboxyterminal peptide of the hCG molecule. Amino acid substitution
affecting biological activity of hCG has not been reported to date, but variation in
the carbohydrate content is well documented (45-49,98,104) and this could affect
the biological activity and/or the half-life of hCG
(17,46,48-54,59,64,65,66,75,120). Purified hCG separated by isoelectric
focusing fractionates into several components in the pH range 3.6- 6.7 (53,55).
The isoelectric points of the major fractions were shown to correlate with their
sialic acid content, the more acidic fractions containing more carbohydrate (53).
An acidic variant isolated from the urine of patients with trophoblastic tumours
appeared to be a potent thyroid stimulator in a bioassay measuring T3 release from
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human and porcine thyroid slices (19). A more recent study of chromatofocused
fractions from partially purified hCG found that some fractions displayed greater
thyrotropic activity than others using a rat thyroid cell (FRTL-5) bioassay (122).
It is possible to speculate that some or all pregnant women transiently produce
greater amounts of a more thyrotropic form of hCG and/or more hCG per se. If
the time during which the more thyrotropic form and/or the higher production rate
of hCG is short, then the time of hyperstimulation of the thyroid would be too
short to cause thyrotoxicosis. However, if the combination of potency and
quantity of hCG reached significant thyrotropic-stimulating levels for a longer
period hyperthyroxinaemia or thyrotoxicosis would result. The thyrotoxicosis
could, in turn, cause emesis or hyperemesis gravidarum (Figure 9). This could
explain the transient nature of pregnancy-associated hyperthyroxinaemia( and
hyperemesis gravidarum) and could explain why clinical thyrotoxicosis does not
occur in the majority of pregnant women.
An alternative explanation would be that the variation is within the thyroid
receptor, but there are no reports of this so far, and this possibility will not be
further explored.
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Figure 9







a more thyrotropic variant
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2.4. The FRTL-5 Bioassay System for Measuring
Thyrotropic Activity
2.4.a. Description of the FRTL-5 Bioassay System
The functional, continuous clonal cell-line of Fisher rat thyroid cells (FRTL) was
first described by Ambesi-Impiombato, Parks and Coon in 1980 (42). This
continually proliferating cell-line, which has remained differentiated and
non-transformed over many serial passages and several years, shows an absolute
requirement for TSH, insulin, somatostatin and transferrin (42,173,174). A
substrain of the original FRTL cells (FRTL-5) was grown in medium
supplemented with 5% newborn calf serum and displayed a much reduced
doubling time of 30 hours, as opposed to 5-7 days in the original FRTL cells (42).
FRTL-5 cells retain the thyroidal characteristics of thyroglobulin secretion and
iodide concentration, and thyrotropic stimulation of the cells can be assessed by
using 3 response signals:
i. iodide uptake




FRTL-5 cells retain the ability to concentrate ioclicle, but coo not appear to organiry
the iodide to any significant amount (42,175). Measured uptake is the balance
between influx and efflux of iodide, and while influx is known to be associated
with an increase in cAMP, factors affecting the rate of efflux are not clear
(175,176). Different thyroid stimulators may have different potencies with regard
to influx and efflux of iodide, and so may not be directly comparable using this
method of measuring thyrotropic stimulation. In addition, iodide uptake is a
time-consuming and technically demanding assay susceptible to large variation.
Nevertheless, iodide uptake by FRTL-5 cells has been frequently used as it
displays high sensitivity, response to 1mU/l TSH being reported
(20,21,121,174,177).
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ii. Increase in adenylate cyclase activity
FRTL-5 cells respond to thyrotropic stimulation by increasing adenylate cyclase
activity and, thereby, intracellular cAMP levels (21,174,175,177-182). When the
cells are stimulated under hypotonic conditions (183), cAMP response is increased
and extracellular cAMP levels rise in parallel with intracellular formation. This
modification obviates the need for extraction of the intracellular cAMP, the
measurement being made instead directly on the medium bathing the cells.
cAMP response is further potentiated by forskolin, an adenylate cyclase activator,
and isomethylbutylxanthine (IBMX), a phosphodiesterase inhibitor. When these
were used in low doses not in themselves stimulatory, increased sensitivity and
precision were obtained (180,184).
This bioassay system is therefore capable of a sensitivity approaching that of the
iodide uptake test and with higher precision. However, the method also requires
the use of an isotope and specialised, expensive equipment as well as a high level
of technical expertise.
iii. Growth
FRTL-5 cells have a doubling time of about 30 hours when maximally stimulated,
and growth drops to zero in the absence of any thyrotropic stimulation. Rate of
growth can be measured as an index of the thyrotropic activity of test stimulators,
and the growth of FRTL-5 cells can be assessed by measuring:
[ 3H I or[ 14C] thymidine incorporation (21,174)
cell number (174)
rate of mitosis (185,186
total protein levels and/or dehydrogenase activity in the cells (43
Radioactive thymidine incorporation is a reflection of the rate of DNA synthesis
and therefore a direct measurement of growth. The cells are deprived of TSH to
desensitise them and reduce the rate of growth to basal levels. The cells are then
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incubated with the test stimulator and [3H] or [14C] thymidine added.
Radioactivity uptake by the cells is then measured (21,174).
Cell number in the presence and absence of test stimulator may be measured by
using a Nebauer counting chamber or a Coulter counter (174). This method of
assessing cell growth is, in theory, a simple and direct one, but has practical
problems in that FRTL-5 cells adhere to the microculture well surface and must be
trypsinised to release them into suspension for counting. If this process is
incomplete, erroneously low counts will be obtained, while over-enthusiastic
treatment may damage and fragment the cells.
Measuring the rate of mitosis can be done using the Mitotic Index Assay
(185,186). This is a direct measurement of growth in which the rate of
mitogenesis is assessed by counting the number of mitotic figures per thousand
cells and expressing this as a percentage. FRTL-5 cells deprived of TSH for 7
days are incubated with the test stimulator for 47 hours. Colcemid, a mitotic
spindle poison, is added at 44 hours to arrest mitosis, and the cells stained and
examined microscopically. The mitotic figures are easily discerned by the
experienced observer and the results are unequivocal. However, this is a time
consuming and labour intensive test and exhibits rather low precision, with a
coefficient of variation of around 20.
A recently applied innovative technique to assess cell growth is the Eluted STain
Assay, or ESTA (43), in which stain formed or taken up by the cells is eluted and
the absorbance of the eluted stain read using a microtitre plate reader. As
mitogenesis increases so too do the protein levels and dehydrogenase activity of
the cell culture, and these two indices of growth can be measured by the ESTA
method using napthol yellow S and tetrazolium salt reduction/formazan formation
staining methods respectively. These staining reactions take place within the
microculture plate wells, and the test is technically simple. The method requires
no isotopes or expensive, specialised equipment and the precision is good, with a
coefficient of variation of around 6%. The sensitivity of the test approaches that
of the cAMP bioassay.
2.4.b. Characterisation of FRTL-5 Response to Human and Bovine
TSH
Various preparations of both human TSH (hTSH) and bovine I SH( b1 SM)
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have been tested using the FRTL-5 cells, including: partially purified bTSH
(Thytropar, Armour Pharmaceuticals Co.), highly purified bTSH( First
International standard 53/11), highly purified hTSH( Second International
Preparation 80/558), highly purified hTSH (First International Preparation
68/33)and purified hTSH( 81/502). The response of the FRTL-5 cells to these
TSH preparations has been characterised using the various bioassay response
signals described in the previous section.
FRTL-5 cells have an absolute requirement for TSH, and when deprived of
thyrotropic stimulation iodide uptake, DNA synthesis, cAMP levels and
mitogenesis decrease to basal levels (42,175,185). When restimulated with TSH,
growth and function of the cells are restored, but the time course of response is
different between the different parameters. cAMP and iodide uptake responses are
acute upon restimulation, and the magnitude of response increases with the time of
TSH deprivation. Maximum response is found after 10 days in TSH-free medium,
by which time the response is twice that of cells deprived of TSH for 1 day before
restimulation (174,180). In comparison, stimulation of growth rate wanes as the
time of TSH deprivation increases, and after 10 days without TSH a 24 hour lag
phase is displayed upon restimulation, ie, no growth is apparent until after 24
hours incubation with TSH, after which growth resumes at an apparently normal
rate (174,180,185).
Dose-response relationships have been investigated using iodide uptake, CAMP
response and the Mitotic Index Assay. Iodide uptake showed a bell-shaped
dose-response curve with a maximum response at 1 U/1 bTSH and significantly
lower responses with higher doses, while CAMP response did not plateau when
tested against bTSH up to 5 U/1 (178,179). Mitogenesis, measured using the
Mitotic Index Assay, showed a maximum response at 1 U/1 bTSH, 10 U/1 giving a
slightly decreased rate of mitosis (185).
Hormonal specificity and relative potencies have also been studied, as has the
FRTL-5 response to non-hormonal factors such as forskolin, IBMX and
epidermal growth factor (EGF). Bovine and human TSH gave different but
parallel dose-response curves when tested using cAMP (179), iodide uptake (21),
Mitotic Index Assay (185) and ESTA (43) bioassay response systems. Bovine
TSH was more potent than human TSH by all methods, but the potency factor
varied from approximatly 2, using cAMP response (178,179), to 17 using iodide
uptake (21). Human thyroid cell monolayer cultures have also been reported to
give a potency ratio of 2 using cAMP response to bTSH and hTSH (179), and
these results imply that human thyroid and FRTL-5 cells may have similar
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discriminatory powers and the same relative dose-response characteristics, and
that the TSH receptor has separate, but linked, functional domains for the various
bioeffects of thyrotropic stimulation. Forskolin and IBMX, both individually and
together, stimulated mitogenesis but EGF did not (180,184). Forskolin is an
adenylate cyclase activator and IBMX is a phosphodiesterase inhibitor both
therefore increase cAMP levels. Since both were found to stimulate mitogenesis,
the role of cAMP in growth of cells was studied. Addition of dibutyryl cAMP
was found to increase the mitotic index and[ 3H] thymidine incorporation into
DNA, and these results support the theory that cAMP has a role in stimulating
growth and that an increase in cAMP levels is a positive signal for growth in
FRTL-5 cells (184).
Non-TSH hormonal preparations tested against FRTL-5 cells include FSH, LH
and hCG. FSH and LH did not appear to stimulate mitogenesis (185), although
both were tested in low doses, but hCG has been shown to exhibit weak
thyrotropic powers using iodide uptake (20,21), cAMP response (21) and rate of
mitogenesis signal systems (43,185).
2.4.c. The Use of FRTL-5 Bioassay Systems in Measuring the
Thvrotropic Activity of hCG
hCG has been found to have thyrotropic activity in murine, bovine and human in
vitro and in vivo bioassay systems (14-21,118,119,122), but the thyrotropic
activity is weak. A figure of 1/5000th that of TSH was suggested by early
investigators using the McKenzie mouse bioassay (115,161), but figures obtained
since vary greatly, one recent report proposing that 1mU of bTSH was equivalent
to 42,000 IU hCG (21). The bioassay used must therefore be both sensitive and
precise if reliable assessment of the thyrotropic activity of hCG is to be made. The
FRTL-5 cells offer such a bioassay system and have recently been used to
measure the thyrotropic activity of partially purified, commercial hCG and highly
purified hCG.
Response systems used have included iodide uptake, cAMP response
(20,21,122), [3H] thymidine uptake (21) and growth measurement using ESTA
(43). Ballabio and co-workers (20) found definite thyrotropic activity in hCG
using iodide uptake as the measured response, and this appeared to parallel the
response to bTSH, lumol of bTSH giving an reponse equivalent to that of
20,000 umol hCG. However, pre-treatment with anti-hCG did not eliminate the
thyrotropic activity in the hCG preparation. This conflicts with previous findings,
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in which removal of hCG by anti hCG also removed thyrotropic activity (14.
Hershman et al (21) recently found a dose-related increase in iodide uptake,[ 3H]
thymidine incorporation and cAMP response of FRTL-5 cells at hCG
concentrations 100 IU/ml, with parallel response to bTSH and hTSH. The
potency ratios of bTSH (mIU) to hCG (IU) was 24,000 for highly purified
hCG and 42,000 for partially purified hCG, ie, 1 mU of bTSH gave equivalent
thyrotropic stimulation as 24,000 IU of highly purified hCG and 42,000 IU of
partially purified hCG. Using the ESTA system, Ealey and co-workers found
significant stimulation of FRTL-5 growth at hCG levels 56 IU/ml (43).
2.5. Summary and Formulation of Hypothesis to be Tested
i hCG is produced in large amounts during pregnancy, particularly during
the period of 8- 12 weeks gestation, and even greater amounts than
normal may be produced by women with hyperemesis gravidarum
(6,8,9,101-104)
Hyperemesis gravidarum is characterised by intractable vomiting andii
usually develops during the 8- 12 week gestation period (1,2)
A significant number of women( more than 30%) with hyperemesisiii
gravidarum have been reported to have clinical and/or biochemical
thyrotoxicosis (25,40,135,170)
Transient pregnancy-associated thyrotoxicosis has been reported in
otherwise normal women in early pregnancy: these women may
spontaneously recover normal thyroid function in later pregnancy, a time
at which their hCG levels are around 10% of the peak levels reached
during the first trimester (22,26,28,29,36,135,155)
Other conditions associated with gross hCG production, eg gestational
trophoblastic disease, have also been associated with thyrotoxicosis
30-38,162-167)
hCG has been found to have weak thyrotropic activity
vi
(13-21,118,119,185)
Vomiting may be the presenting feature of thyrotoxicosis (41)Vii
vi
v
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viii
Hyperthyroidism may present as hyperemesis gravidarum (28,29
Since hCG levels in early pregnancy, gestational trophoblastic disease and in
various malignant conditions may be well above 100 IU/I x10-3, the weak
thyrotropic activity of hCG could become significant. The upper limit of normal
for TSH in serum is around 5 mIU/l, the thyrotropic activity of which could be
emulated or surpassed by the very high levels of hCG found in these conditions.
The hCG-related thyrotropic activity could lead to clinical thyrotoxicosis and/or
hyperthyroxinaemia, increased serum free thyroxine levels, reduced serum TSH
levels and suppression of response to exogenous TRH, findings which have
previously been reported in patients with conditions linked to high hCG
production (124,125,126,135,145,146,148,154,155).
However, most pregnant women do not develop thyrotoxicosis, even though their
serum hCG levels are undoubtedly high. That clinical over-stimulation of the
thyroid by hCG does not occur in the majority of pregnant women may be due to
intra-individual differences in thyrotropic activity of the hCG, which could be due
to structural variation, eg amino acid substitution, or in the degree of glycosylation
of the molecule. It should be also be remembered that anxiety, tachycardia,
diaphoresis and heat intolerance are commonly found in normal early pregnancy,
as are nausea and vomiting, (1,2,24,136), and undetected, transient,
hCG-induced thyrotoxicosis could be the cause. The FRTL-5 bioassay for
thyrotropic activity offers a possible means of investigating and comparing the
thyrotropic activity of hCG from different women and at different stages of
pregnancy. Results of such a study could explain why some patients with grossly
elevated hCG remain completely euthyroid, while others with relatively modest
hCG concentrations develop hyperthyroxinaemia.
From the observations summarised above, it is possible to postulate that hCG is
the causal factor in the development of pregnancy-associated hyperthyroxinaemia
and that women with hyperemesis gravidarum have developed the condition
because of thyroid overstimulation due to the production of more hCG per se, a
more thyrotropic form of hCG or both. This general postulation contains the
hypothesis to be tested by this research project, namely:
Women with hyperemesis gravidarum have over-stimulation of the
thyroid due to hCG- more hCG per se, a more thyrotropic form or a
combination of both.
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Chapter 3 MATERIALS AND METHODS
3.1. Patients Samples and Information
3.2. Extraction and Purification of hCG
a. ammonium sulphate precipitation
b. Concanavilin A sepharose extraction, buffer exchange and
concentration
c. gel filtration (Biogel P100)
d. DEAE ion-exchange chromatography
3.3. Dialysis
3.4. Freeze Drying
3.5. Detection and Measurement of hCG
3.6. Measurement of Total Protein
3.7. Measurement of Creatinine
3.8. FRTL-5 Bioassay for Thyrotropic Activity
3.9. Isoelectricfocusing and Immunoblotting of hCG
3.10. Statistical of Results
All reagents were purchased from BDH unless otherwise specitied.
* Denotes work done at the Department of Chemical Pathology Research
Laboratory, University College Hospital, London. All other work was performed
in Hong Kong.
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3.1. Patients' Samples and Information
Samples were collected from women admitted to The Prince of Wales Hospital,
Shatin, Hong Kong and diagnosed as suffering from hyperemesis gravidarum.
With the one exception all women were Chinese. Blood was taken at or around the
time of the urine collection and an aliquot of serum stored at -40°C until assay for
hCG by an enzyme-linked immunoassay method( Hybritech). This blood
sample was also used by the routine Chemical Pathology Department at the Prince
of Wales Hospital for measurement of serum total thyroxine (T4) by an EMIT
assay, serum TSH by an ultra-sensitive chemiluminescent method and RBC zinc.
Red blood cell zinc was used to assess the length of time since the thyrotoxicosis
had developed, as it has been reported that this parameter is low in thyrotoxicosis
of more than a few months duration (187,188). Normal red blood cell zinc would
therefore be found in in association with thyrotoxicosis of recent onset, such as
transient pregnancy- (or hCG-) associated thyrotoxicosis. Any patient showing a
low RBC Zn would therefore be excluded from the study, however, no low RBC
levels were reported. 58 blood samples were received and tested. Patient




T4, TSH and RBC zinc results.
Serum hCG, urine and eluate hCG, urine creatinine, urine and eluate total protein
and thyrotropic activity were all measured as part of the project work.
Suitable urine samples from 17 hyperemesis patients were received and processed.
The requested urine sample was overnight urine and /or early morning urine
collected into a plain plastic container and these were stored at -40°C until
processed.
Dialysed, but otherwise untreated, urine and dialysed eluate were treated
identically throughout the processes of freeze-drying, storage, transport,
reconstitution and bioassay, and in the hCG and protein measurements. Results
obtained from the FRTL-5 bioassay were translated into units/ml of 'apparent
hCG' by comparison with a dose-response curve obtained using commercial,
partially purified hCG.
An overview of the experimental design is given in Figure 10.
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3.2. Extraction and Purification of hCG
3.2.a. Salt extraction using ammonium sulphate precipitation
Initially, a final concentration of 26.4% ammonium sulphate in urine was used,
with overnight precipitation of proteins at 4°C, followed by centrifugation and
collection of the precipitate, which was redissolved in H2O before further
processing. Recovery of hCG was, however, disappointingly low (see Tables 3
and 4 in Results section). Recovery improved with increasing concentrations of
ammonium sulphate, but, as hCG is known to dissociate into free alpha and beta
subunits when exposed to high salt concentrations, this initial step was deleted
from the experimental design and hCG extraction was made directly from urine
using Concanavilin A Sepharose.
3.2.b. Concanavilin A Sepharose (Con A) affinity chromatography
( Fij-ure 11, buffer exchange and concentration
Materials
1 0.05 mol/l phosphate buffer in 0.5 mol/l NaCl, pH 7.2, 0.02% sodium azide
added (PBS starting buffer)
2 Pharmacia Concanavilin A Sepharose( Con A): 50% w/v solution in PBS
starting buffer
Eluting buffer: 0.5 mol/l alpha methylmannoside in PBS starting buffer3
100ml plastic centrifuge tubes with caps4
Roller mixer5
6 Refrigerated centrifuge (MSE Coolspin 2)
Tris/HCl buffer: 0.02 mol/l, pH 8.0, 0.02% sodium azide added7
8 Amicon micro-filtration unit( 1Omi size) with YM Diaflo R ultrafilters,
molecular weight > 10,000 retained.
Procedure
100 ml centrifuged urine was mixed with 40 ml 50% Con A in PBS starting1
buffer and added in equal quantities to 2 plastic centrifuge tubes
1) Tubes were capped and adsorption allowed to proceed at room temperaturer
for at least 4 hours with continuous, gentle mixing
Tubes were centrifuged for 5 minutes at approximately 2,500 rpm3
supernatant discarded
Con A was washed by addition of 75 ml PBS starting buffer, followed by4
centrifugation and removal of supernatant
Wash step was repeated: buffer supernatant decanted5
10 ml eluting buffer was added to each tube6
Elution was allowed to proceed for at least 4 hours at room temperature with7
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Figure 11
Concanavilin A sepharose tube procedure for extraction of
hCG from pregnancy urine
50 ml urine +20 ml 10% Con A Sepharose
mix at R.T for
>4 hours
spin 2,500 rpm 5
(1) (2) discard(3)
supernatant
mix at R.T. 4 hours then spin,
collect and store supernatant 10 ml eluting buffet 75 ml buffer wash x 2
and spin
(6) (5) (4)
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continuous, gentle mixing
8 Tubes were centrifuged for 5 minutes at approximately 2,500 rpm
9 Supernatants were collected and pooled (20 ml in total)
10 Con A was regenerated (Appendix 1)
11 20 ml eluate in eluting buffer was reduced to approximately 6 ml and buffer
exchanged for 0.02 mol/l Tris/HCl, using the Amicon micro- filtration
apparatus (Appendix 2)
3.2.c. Bioizel P100 eel filtration chromtnQrnnhv
Materials
1 Biorad B iogel P 100 gel filtration beads
2 Tris/HCl buffer 0.02 mol/l, pH 8.0
3 Pharmacia column, K 26/100 with LV2 triple port valve and R25/25 reservoir
4 LKB 2232 Microperpex peristaltic pump
5 Isco UA5 detector with Isco type 6 optical unit (280nm)
6 Pharmacia FRAC 100 fraction collector
7 LKB Minicoldlab cold cabinet (4°C)
8 Biorad gel filtration standards
Highly purified hCG( 3rd International Standard code no. 75/537, kindly9
supplied by the National Bureau of Standards and Control, Blanch Lane,
South Mimms, Herts., UK)
10 10 ml plastic syringe barrel with a Millipore AP 25 pre-filter inserted
Procedure
Biogel (porous polyacrylamide beads with a stated fractionation range of S,UUU
100,000 daltons)was prepared according to manufacturer's instructions and the
prepared column of 2.6 x 80 cm kept at 4°C. Calibration was performed using
Biorad gel filtration standards and highly purified hCG and conditions kept
constant thereafter. Column characteristics and specifications were as follows:
80 x 2.6 cmColumn size
Tris/HCI, 0.02 mol/I, pH 8.0Buffer
12ml/11AVUrFlow rate
Pharmacia column K 26/100 with LV3 tripleEquipment
port valve (LKB 2023) and R 25/26 550
ml reservoir
LKB 2232 Microperpex S peristaltic pump(in Minicoldlab at
Isco UA 5 detector with ISCO type 6 optical4 °C)
unit
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Pharmacia FRAC 100 fraction collector
Vo column= 114 ml
Ve albumin= 144- 160 ml




A 10 ml plastic syringe with a Millipore AP 25 pre-filter was connected to the
column through the triple port valve and samples added to the column through this
by gravity flow. Bio-rad gel filtration standards were run to initially calibrate the
column, and then highly purified hCG( 3rd International Standard, kindly
supplied by the National Bureau of Standard and Control, Blanche Lane, South
Mimms, Herts., England) was used to calibrate the elution volume of dimer hCG.
During calibration and in use, the hCG- containing fractions were initially
identified using the semi-quantitative Tandem Icon assay. Recovery was assessed
using the Hybritech Tandem E enzyme- immunometric assay both these methods
are described in Appendix 3. Approximately 5 ml sample from Con A step was
added to the column by gravity flow, after which the flow rate was
maintained at 12 ml per hour and 4 ml were fractions collected. hCG-containing
fractions were identified by the Hybritech Tandem Icon test and pooled.
3.2.d. DEAE-cellulose ion-exchange chromatography (Figure 12)
Materials
Whatman 52 DEAE-cellulose1
1 x 8 cm plastic syringe barrel with glass wool plug and small bore teflon2
tubing
Tris/HCl buffer 0.02 mol/l, pH 8.03
Eluting buffer: 0.02 moll Tris/HC1 buffer in 0.5 mol/I NaCl, pH 8.0, 0.02%4
sodium azide added
Method
DEAF cellulose was swollen in 0.02 moll Tris/HCl and 8 ml poured into1
a plastic syringe barrel the column was originally calibrated at room
temperature using urine of known hCG content.
Pooled fractions from Biogel column were added manually to the DEAE2
"columu and washed through with 3 column volumes of 0.02 mol/1 Ths/HC"
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Figure 12
DEAE cellulose ion-exchange chromatography of pooled
hCG containing fractions from Biogel column.
1Oml PLASTIC
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buffer( gravity flow
3 hCG was eluted with eluting buffer and eluate volume 5-10 ml collected
('eluate')
4 Eluate was stored at -70°C until dialysis




1 Deionised and distilled H2O
2 Dialysis tubing( Sigma) 23 x 15 mm: molecular weight cutoff 12,000.
Method
5 ml DEAE eluate and 5 ml untreated urine from each patient were sealed into
dialysis tubing bags and dialysed separately against deionised, distilled H2O for
50-60 hours at 4°C with frequent changes of water. Dialysed samples were then
aliqoted for hCG, total protein and thyrotropic activity measurements and stored at
-70°C.
3.4. Freeze drying
Overnight freeze drying of 3 ml aliquots of eluate and dialysed urine in glass vials
was performed using an Edwards Super Modulyo Pirani 1001 freeze dryer. Glass
vials were then sealed and transported from Hong Kong to London, where they
were stored at room temperature until reconstitution and bioassay.
3.5. Detection and measurement of hCG (see Appendix 3 for test
specifications)
Materials
Tandem Icon semi-quantitative method for detection of hCG1
Diagnostics Products Corporation (DPC) radioimmunoassay method for total2
beta hCG
Hybritech enzyme immunometric method for dimer hCG3
4 Hybritech Photon Era
5 Packard Autogamma 5780 counter
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Metlwa
Samples to be quantitated( serum, urine and eluate) were diluted in zero calibrator
or 5% w/v human albumin in distilled H2O and then measured for hCG following
the manufacture's instructions. Dimer hCG levels were obtained for all urine,
eluate and serum samples: DPC total beta hCG results were primarily used in the
early stages of calibrating the purification steps.
3.6. Measurement of total protein( method of Bradford) (189)
Materials
1
Biorad reagent( coomassie blue in phosphoric acid) for micro total protein
measurement, diluted 1/2 in distilled H2O immediatly before use.
2 Human albumin (Sigma) 20 mg/I
Cobas Bio centrifugal analyser
Method
The method was adapted from manual Biorad method for the Cobas Bio
centrifugal analyser, the settings of which are given below. Samples for total


















The test was linear from 5- 25 mg/1 and the precision was as follows:
n=10cv=40%n=10cv= 10.3% 20 m /l5 mg/lin run
n=9cv=4.1%between rur 10mg/l
3
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3.7. Measurement of creatinine
Materials
1
Chemlab continuous flow system with standard creatinine manifold employing
the Jaffe reaction: 45 second sample time 15 second wash time, 505nm filter
(Appendix 4)
2 Saturated picric acid solution
0.5 moll NaOH
4 0.15 moll NaCl
5 Aqueous creatinine standards
Method
Undialysed urine samples were diluted in distilled H2O and measured following the
Chemlab manufacturer's instructions (Chemlab Instruments Ltd., Essex, UK).
3.8. Thyrotropic activity biomeasurement( Figures 13 and 14
Materials
(for exact concentrations of solutions and detailed procedures see Appendix S)
1 FRTL-5 cells maintained as stock culture in Coon's modified F12 medium
supplemented with 5% newborn calf serum and, per ml, 100 units penicillin,
100 ug streptomycin, 10 ug insulin, 10 nmol cortisol, 5 ug transferrin, 10 ng
L-glycly-L-histidyl-L-lysine acetate, 10 ng somatostatin and 1 mU TSH. This
medium is referred to as 6H
2 5H medium: as 6H without TS H
3 Staining reagents: MTT (3-[4,5-dimethylthiazol-2yl]-2,5-di-phenyl-
tetrazolium bromide) and Napthol Yellow S
4 Bovine TSH (Thytropar) Armour Pharmaceuticals Ltd, Eastbourne, Sussex,
UK
Human TSH: the Second International Reference Preparation 80/558, kindly5
supplied by The National Bureau of Biological Standards and Control, UK
International Reference Preparation of hCG 3rd International Standard 75/5376
kindly supplied by the National Bureau of Standards and Control, UK
Partially purified hCG( Gonadotrophon L.H.) Payne and Byrne Ltd,7
Greenford, Middlesex, UK
Working FRTL-5 cell cultures: cells were plated out from stock cultures into8
microculture plates at a density of 5 x 104 cells per well( 150 ul stock culture
in 6H). After 3 days incubation, the 6H medium was decanted and replaced
by 5H medium, and the cells maintained for 7 days in this before the addition
of test or standard stimulator, with one change of 5H medium at 3-4 days.
Dynatech microtitre plate reader9
3
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Figure 13
Sample preparation before bioassay for thyrotropic activity
1. - P 0 ml RH IBMX to reconstitute
(1.8 x 10 '6 M)
left overnight at 4° C
Freeze dried samples
original volume= 3.0 ml
2.
Filter through 0.2 ym
filter unit into sterile bottle
3 2 x 600 pi aliquots
into sterile bottles
4.300 jj! 5H IBMX
FRTL Bioassay in quadruplicate
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Figure 14
FRTL-5 bioassay system for thyrotropic activity
FRTL-5 Bioassav for Measuring
Thyrotropic Activity of hCG
FRTL-5 cells from stock
culture (6H medium) plated
out at a density of 5x10
cellsml: 150ui added to





solution added to each
well (in quadruplicate).





O replaced by 150ul 5H
medium (No TSH).
Stimulator 5H medium
decanted:Efuted StainAssay (ESTA) performed
to assess growth
(ie, stimulation).
7 days incubation with
one change or 5H medium
atter 3-4 days.
Absorbance of each well
read in microtitre plate
reader: x of 4 wells read
off hCG dose response
curve and translated into
u ml 'apparent hCG'.
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10 Disposable sterile plastic 5 and 10 ml pipettes and 1.0 ml syringes foi
pipetting
11 Millipore 0.2 um sterile filters
All cell handling was performed using aseptic technique in a laminar flow cabinet.
Incubation of stock and working cultures was at 37°C in a humidified atmosphere
containing 5% COo.
Sample Preparation (Figure 13)
Freeze-dried samples of dialysed urine and eluate were reconstituted with 5H to
their original volume, left overnight at 4°C and filtered through a Millipore 0.2um
sterile filter.
Hormone preparations for dose-response curves
Highly purified hCG, partially purified hCG and highly purified hTSH were
reconstituted with a known volume of 5H and the stock hormonal standard
solutions were filtered through Millipore 0.2 um filters to sterilise. The standard
preparation of bTSH used was 6H (1 Ul bTSH) diluted in the appropriate amount
of sterile 5H.
Metliod (Figure 14)
After 7 days incubation in 5H, the medium was decanted and 150 ul test stimulator
or standard dose of hCG or bTSH was added to each well. Bach test sample and
standard was put up in quadruplicate and 4 wells in each plate received 150 ul of
5H medium only. The cells were incubated for 48 hours and the staining
procedure carried out as follows:
MTT stain for dehydrogenase activity: 15 ul of 5 g1 MTT solution in Dulbeccos
PBS was added to each well for 15 minutes, after which the medium
was removed by decanting and the stain eluted from the cells with 100 ul acidified
isopropanol. Absorbance at 570 nm with a reference wavelength of 630 nm was
read against an air blank using the Dynatech microtitre plate reader, after which the
acidified isopropanol was decanted, the plate dried overnight at room temperature
and the Napthol Yellow protein staining method performed by adding 100 ul of
lg1 napthol yellow S in 1% acetic acid to each well and staining for one hour;
excess stain was removed by washing the plates in 1% acetic acid and the stain
eluted with 100 ul of 0.25 molA NaOH. Absorbance of the eluted stain was read
at 410 nm (air blank, reference wavelength 630 nm) and the mean and standard
deviation of the quadruplicate readings was calculated. Using the dose-response
curve obtained with known amounts of hCG, absorbance readings for the test
samples were translated into unitsml of apparent hCG (A hCG). Units of apparent
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hCG were then related to the known, immunological content of hCG in the sample
(M hCG) and the A/M hCG ratio calculated.
3.9. Isoelectricfocusing and immunoblotting of hCG
(190,191)
Materials
(for exact concentrations of solutions and more detailed procedures, including
preparation of polyacrylamide gel, refer to Appendix 6)
Materials
for isoelectricfocusing
1 10% polyacrylamide gel, 200 x 100 x 0.45 mm, volume= 9 ml, T/C= 10/15,
containing ampholines (Pharmacia and LKB) to cover the pH range 3-10
2 Pharmacia flat bed apparatus FBE 3000 with cooling plate
3 0.8 mol/1 NaOH
4 0.5 moll H3PO4
5 Whatman No. I filter paper applicators 7 x 3 mm
6 Whatrnan 17 mm chromatography paper wicks, 200 x 8 mm
7 LKB Macrodrive constant power supply
8 Amicon Centricon 3 microconcentrators (molecular weight 3,000 cutoff)
Bio-rad D6 PG disposable desalting columns (molecular weight 6,000 cutoff)9
for transfer
1 Nitrocellulose membranes (LKB BA 85), 0.45um thick, cut to fit gel
Cellulose acetate membranes (Schleicher and Schuell, West Germany OE67)2
0.45 thick, cut to approximately 190 x 90 mm
Whatman No. 1 filter paper circles, 7 mm diameter, cut in halfJ
4 Bio-rad transblot cell
Whatman 3 mm chromatography paper, 200 x 110 mm5
6 0.05 mol/1 Tris/borate buffer, pH 8.0, containing 5% methanol (transfer
buffer)
0.05 mol/1 Tris/borate buffer, pH 7.2, containing 0.1% Tween 80 (blocking7
buffer)
0.05 mol/l Tris/borate buffer, pH 7.2 (wash buffer)8
9 Model 200/2.0 Bio-rad power pack
for immunological reactions ana visuausauon uj jucuaeu Uu/LU.J
Rabbit anti-hCG-beta immunoglobulin (Dakopatts, Copenhagen, Denmark),
1
in appropriate dilution
Swine anti-rabbit immunoglobulin (Dakopatts, Copenhagen, Denmark),
2
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diluted 1175
3 Rabbit anti-peroxidase (Dakopatts, Copenhagen, Denmark), diluted 1/10
4 Horseradish peroxidase (Type II, ,Sigma), 0.04 mg/ml
5 3,3' diaminobenzidine tetrahydrochioride( Sigma) (DBZ) 10 g/l
6 H202 32% v/v
7 0.1 mol/I Tris/HC1 buffer, pH 7.2( staining buffer)
8 0.05 mol/I Tris/borate buffer, pH 7.2, containing 0.1% Tween 80 (blocking
buffer)
9 Shandon horizontal electrophoresis tank and power pack
10 Cellulose acetate membrane applicator strips, 200 x 10 mm
Method
1 Isoelectricfocusing (191)
Following the procedures detailed in Appendix 6, a polyacrylamide gel( 200 x
100 x 0.45 mm) containing ampholines to cover the pH range 3-10 was prepared.
The gel was placed on a cooling plate (100C)and electrical connection made via
Whatman No 17 mm chromatography paper wicks soaked in 0.8 moll NaOH
(cathode) and 0.5 moll H3PO4 (anode). The gel was pre-focused for 2 hours at
700V after which samples were applied to the cathode end of the gel using two 7 x
3 mm Whatman No. 1 filter paper applicators. The samples (urine) were run into
the gel for 30 minutes at 700V and, after removal of the sample applicators,
focusing proceeded for 2 hours at 2,000V and then 2,500V for 30 minutes. The
urine samples had been desalted using the Bio-rad disposable desalting columns
and then concentrated x 30 (approximately) using the Amicon microconcentrators.
Partially purified, commercial hCG (Sigma) was also concentrated and run on the
gel for comparison with the urine samples.
2 Transfer of hCG to nitrocellulose (190)
Transblot apparatus containing the cooling grid was filled with 2 litres of transfer
buffer at 4°C. Sponges, filter paper, chromatography paper and cellulose acetate
and nitrocellulose membranes were soaked in transfer buffer and all air bubbles
extruded. Buffer-saturated cellulose acetate membrane, then filter paper,
nitrocellulose membrane and two layers of chromatography paper were carefully
placed on top of the focused gel. This was covered by a thick wad of absorbant
paper, evenly weighted (to ensure even passive transfer) and left for 10 minutes.
Absorbant paper and one layer of chromatography paper were then removed and
the assembly inverted onto a transblot sponge saturated in transfer buffer. This
was left for 10 minutes before removal of the gel support sheet. Chromatography
paper was placed on top of gel and the transblot sandwich (see Appendix 6)
enclosed in the plastic frame, after which the whole assembly was placed in the
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transblot cell with the nitrocellulose membrane facing the anode. Electrophoretic
transfer proceeded for 5 minutes at 50V and then 1 hour at 120V, after which the
nitrocellulose membrane was washed in washing buffer. Remaining protein
binding sites on the nitrocellulose were then blocked by incubating in blocking
buffer for 1.5 hours at 37°C.
Immunological reactions and visualisation of focused bands (191)
Antibodies to hCG, rabbit and peroxidase were added sequentially to the
nitrocellulose membrane using cellulose acetate applicator strips soaked in 100 ul
of diluted antiserum and the technique of immunoelectroendosmosis using the
Shandon electrophoresis tank as described in Appendix 6. The nitrocellulose strip
was then floated in freshly made up dye solution comprising 100 ml staining
buffer, 100 ul H202 and lml (10 mg) DBZ to stain the immune complexes.
3.10. Statistical Analysis of Results
Results of patients' samples were analysed using the SPSS PC+ programme
(SPSS Inc., Chicago, USA) and an IBM PC. Dose response curves and graphs
were obtained using Cricket Graph software (Cricket Graph Inc.) and an Apple
Macintosh Plus PC. Statistical tests used included the non-paired Students' t-test
where numbers were acceptable (>50) and distribution of results was similar, and
the non-parametric Mann-Whitney ranking test for those tests which had few_
(<10) results. The male/female ratio of babies was tested for significant difference
from the expected ratio using the chi-squared test. Correlation between parameters
was assessed using the Pearson ranking correlation test.
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Chapter 4 RESULTS
4.1. Serum hCG Levels and Thyroid Function in Hyperemesis
Gravidarum
4.2. Purificationf of hCG.
4.2.a. Ammonium sulphate precipitation
4.2.b. Con A sepharose extraction
4.2.c. Biogel gel filtration chromatography
4.2.d. DEAE ion-exchange chromatography
4.2.e. Overall increase in specific activity after purification
4.3. Evaluation of FRTL-5 Bioassay System for Measurement of
Thyrotropic Activity of hCG from Preinancv Urine
4.3.a Effect of urine+/- hCG on FRTL-5 cells
4.3.b Dose response curves and relative potencies of bTSH,
hTSH, IRP hCG and partially purified hCG using ESTA
MTT and NYS stains with and without potentiation of
FRTL-5 response with IBMX
4.3.c. Precision of bioassay
4.4. The Thyrotropic Activity of hCG from Women with
Hyperemesis Gravidarum
4.5. Isoelectricfocusing and Immunoblotting of hCG
4.6. Pregnancy Outcome with Reference to the Sex of the Baby
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4.1. Serum hCG levels and thyroid function in
hyperemesis gravidarum
Serum hCG, T4 and TSH were measured on 58 hyperemetic patients. hCG
measurements were part of the project work and the manufacturer's test
specifications are given in Appendix 3. The in-run and between-run precison of
the hCG assay was as follows:
in-run 25 IU/1 n=8CV 3.8%
300 IU/1 n=8CV 3.0%
25 IU/1between-run n=20CV 7.9%
300 IU/1 n=20CV 10.491
T4 and TSH measurements were done by the routine Chemical Pathology
Laboratory of the Prince of Wales Hospital, Shatin, Hong Kong. Of the 58
patients studied, 22 (38%) had elevated serum T4 (>140 nmol/1) and 27 (47%)
had serum TSH levels below 0.2 mIU/l, the lower limit of the reference interval.
In no patient was the RBC zinc found to be low (results not shown), implying that
in all cases where high T4 was found this was of recent onset.
The hCG, T4 and TSH results obtained are presented in Table 2 and the
inter-relationships between these variables are presented in Figures 15,16,and 17
and Table 3. The results show a significant positive correlation between the
logarithims of serum hCG and T4 (r=0.27, p<0.05) and a significant inverse
correlation between the logarithims of serum hCG and TSH (r= 0.45, p 0.001)
and serum T4 and TSH (r= 0.41, p0.01). When the effect of gestation was
held constant the correlation between hCG and T4 increased (r=0.36, p < 0.01).
When hCG was held constant the correlation between TSH and T4 was not
significant (r= -0.26) and this may imply some role for hCG in determining the
serum T4 levels of these women. It is apparent, however, that the scatter of
results is wide and that some patients with very high T4 had hCG levels in the
mid-range. The results also show one patient (patient number 40 in Table 2) with
very high serum hCG (422 IU/1 x10-3) with a normal T4 of 73 rmol/l while
another with a similarly high hCG (patient number 41) had an elevated T4.
On the basis of the results presented in Table 2, the patients were divided into 1)
high and normal T4 groups and 2) low and normal TSH groups. The hCG levels
in the different groups were compared and these results are shown in Figures 18
and 19 and Table 4. The scatter of hCG results is wide, but the the results of a
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Student's t-test for unpaired data showed that the mean serum hCG in those
women with high T4 and/or low TSH was significantly higher than the mean hCG
in those with normal thyroid function indices (P=0.05 and P 0.01 respectively
for the T4 and TSH groups).
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Table 2
Serum T4, TSH and hCG levels in hyperemetic women
No T4 TSH hCG Gest No T4 TSH hCG Gest
nmol1 mIU1 IU1 weeks nmol1 mIU1 IU1 weeks
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Figure 15
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Figure 16
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Figure 17
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Figure 18
Comparison of serum hCG levels in hyperemetic women
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Figure 19
Comparison of serum hCG levels in hyperemetic women
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Tahlp T
Correlation between serum hCG, gestational age and thyroid
function in hyperemetic women
Variable Log T4 Log TSH Gestation
Log hCG r 0.274 -0.447 -0.174
n 55 55 47






With the effect of testation held constant
Log hCG r 0.356 -0.432
Log TSH i n iqc
With the effect of hCG held constant
Log TSH r -0.262
= P0.05= P0.01= P0.005
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ToKIA A
Comparison of serum hCG levels in hyperemetic women
with high serum T4 andor low serum TSH levels
TSH mIU/1
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4.2. Purification of hCG
4.2.a. Ammonium sulphate precipitation
The initial plan was to precipitate hCG( and other urinary proteins) using
ammonium sulphate and then to purify this crude extract by sequential affinity, gel
filtration and ion-exchange chromatography. The recovery of hCG in the pilot
study using 26.4% (2.0 mol1) ammonium sulphate was disappointingly low,
ranging from 9- 23%, and, although recovery increased to more than 50% when
higher concentrations of ammonium sulphate were used (Table 5), it was found
that initial precipitation with ammonium sulphate followed by extraction of hCG
with the lectin Concanavilin A showed no advantage over direct extraction of the
urine with Concanavilin A (Table 56. The ammonium sulphate precipitation step
was therefore discontinued after the pilot study.
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Table 5




% Recovery at ammonium sulphate concentration of:
26.4% 30% 40% 50%
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Table 6
Comparison of recovery of hCG after Con A sepharose
extraction of urine with and without
prior ammonium sulphate precipitation step
IU hCG in sample= 600 % Recovery of hCG
40% wv (3.0 mol1) ammonium sulphate precipitation 59
40% wv (3.0 mol1) ammonium sulphate precipitation
followed by desalting (Sephadex G25 column),
concentration and Concanavilin A extraction 28
Direct Concanavilin A extraction
( 4g Con A Sepharose)
46
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4.2. b. Con A sevharose extraction
Because of resource limitations, Con A sepharose extraction of hCG from
pregnancy urine was to be performed using a tube procedure( Figure 11) rather
than the usual column procedure. The relative amounts of hCG, Con A and alpha
methylmannoside( the eluant) to be used in the procedure were determined first.
A. Capacity for adsorption of hCG( IU hCG/g Con A)
Working Con A Sepharose solution was prepared by decanting the original buffer
and washing the Con A with 10 volumes of PBS starting buffer( 0.05 moll
phosphate buffer in 0.5 mol/1 NaCl, pH 7.2). After settling, the wash buffer was
decanted and a 50% w/v solution of Con A in fresh PBS starting buffer was made
up.
Centrifuged urine of known hCG concentration (measured by RIA for total beta
hCG) was mixed with 50% Con A solution in varying ratios to cover the range 14
- 1200 IU hCG/g Con A. The procedure followed was that described in Figure l 1
hCG concentrations of the supernatant and eluant were measured and are shown in
Table 7.
Over the range.of 14- 1200 IU hCG per g Con A, there was negligible hCG in the.
supernatant. hCG recovered in the eluant was around 50% when the amount of
hCG was higher than 160 IU/g.
100 ml( the proposed sample volume to be used) pregnancy urine can be expected
to contain 500-5,000 IU hCG. Using the results of this pilot study, 5 g Con A
Sepharose could be expected to give a recovery of approximately 50% when up to
6,000 IU were added, and so should be sufficient for initial extraction of hCG
from 100 ml of pregnancy urine. However, because of the very wide urinary
hCG range in the project patients, and because the adsorption would in most cases
be performed without prior urinary hCG quantitation, it was decided that 10 g Con
A per 50 ml of urine would be used for the initial extraction of hCG from the
project urine samples.
The apparent loss of 50% of hCG could be due to lack of eluant, and the
possibility that a higher concentration of alpha methylmannoside may elute this
was investigated.
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Table 7
Concanavilin A sepharose recovery study
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B. Concentration of eluant required for maximun recovery of
adsorbed hCG
Approximately 30 IU hCG (5m1 pregnancy urine with a measured hCG total beta
concentration of 5500 IU/1) were mixed with 2g Con A, ie 15 IU/g, in each of 8
tubes. Adsorption, washing and elution were carried out according to the protocol
in Figure 11, with the exception that varying amounts of alpha methylmannoside
were used for elution. No hCG was detectable in the supernatant and the recovery
of adsorbed hCG in the eluant is shown in Table 8.
Increasing the concentration of alpha methylmannoside above 0.6 mmol/g Con A
did not appear to significantly increase the recovery of adsorbed hCG. Using 1.0
mmol/g may give slightly higher recovery of hCG but would be more expensive
and require more time for elimination during the later buffer exchange step, so the
eluant concentration chosen for routine use was 0.5 mmol alpha methylmannoside
per g Con A sepharose (10 ml 0.5 mol/l alpha methylmannoside /10 g Con A).
The question still remains as to the whereabouts of the remaining 50%. hCG from
urine is rather heterogeneous, with varying degrees of glycosylation. It is
possible that some immunologically active beta fragments or deglycosylated forms
remained bound to the Con A, even in the presence of high concentration of
eluant. For the purposes of this project, 50% recovery in this step was regarded
as satisfactory, and the fate of the missing 50% was not investigated.
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Table 8
Concanavilin A sepharose elution study
% recovery ofmmol alpha methyl- hCG concentration
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4.2.c. Biogel gel filtration chromatography
Biorad gel filtration standards and highly purified hCG (3rd International
Preparation (IRP)) kindly supplied by the National Bureau of Standards and
Control, South Mimms, England) were used to calibrate the Biogel column. hCG
had approximately the same elution volume as albumin (148m1), a feature
attributable to the large Stoke's radius of hCG which is conferred by its high
carbohydrate content.. The recovery of highly purified hCG in the eluant volume
148- 176 ml was 50%, but patients' samples showed variable and generally low
recoveries (1-20%). This was presumably due to the presence of large amounts of
small fragments of hCG in pregnancy urine, but no later fractions containing a
large amount of immunologically active hCG could be identified to account for the
loss.
The elution pattern of the Biorad standard is shown in Figure 20 and that of the
hCG IRP shown in Figure 21.
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Figure 20
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Figure 21
Elution pattern of highly purified hCG (IRP) from Biogel
gel Filtration column
30 32 34 36 38 40 42 46 48 50
iSCO INC.
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4.2.d. DEAE ion-exchange chromatography
For initial calibration, 5m1 of Tris/HCl buffer with 5000 IU commercially prepared
hCG (Sigma) was loaded manually onto the column and washed through with 3
column volumes of Tris/HCl buffer (gravity flow, flow-rate approximately 100
ml/hour).
Elution of hCG was performed using 0.5 moll NaCl in 0.02 mol/l Tris/HCl and
eluate fractions of known volume collected manually. The hCG containing
fractions were identified using the Tandem Icon test and the hCG content
measured using the Hybritech Tandem E enzyme-immunometric assay for dimer
hCG as described in Appendix 3. The elution pattern and recovery of hCG from
the column are shown in Figure 22, from which it can be seen that approximately
80% of added hCG eluted in the 5-10 ml elution volume with maximum hCG
concentration in the 6-7 ml elution volume fraction. The recovery of hCG added
in known amounts (500 and 1,000 IU) to the column was also assessed: the
results of this study are shown in Table 9 and were 77% and 87% respectively.
The column was regenerated between samples by washing with 10 ml 3.0 mol/1
KCI followed by 5 column volumes of 0.02 mol/I Tris/HCI.
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Figure 22
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Table 9
Recovery of hCG from DEAE-cellulose column
Sample 1: Sigma hCG in TrisHCl( 5ml)
hCG content of sample= 1000 IU















Sample 2: Sigma hCG
hCG content.of sample= 500 IU
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4.2.e. Overall increase in specific activity after purification
hCG( measured by EIA for dimer hCG) and total protein( measured by the
method of Bradford) concentrations of urine samples were measured before and
after the purification process. The purification process did result in apparent
purification of hCG, as assessed by the increase in specific activity, however,
individual urines showed wide variation in the degree of increase in specific
activity, probably because they contained differing amounts of
immunologically-reactive fragments of hCG which were presumably lost during
the purification procedures. The overall recovery of hCG was low, and varied for
individual urines in the range 1- 14%, and this is probably also a reflection of loss
of small, immunologically-reactive fragments during the gel fltration step and,
perhaps, due to loss of deglycosylated forms during the Con A Sepharose
extraction step.
A table of individual recoveries and increase in specific activity of patients'
samples after purification is shown in Table 10. There was no obvious
relationship between the amount of hCG recovered or the increase in specific
activity (purification factor) and any other parameter, including serum T4, hCG,
initial specific activity of the urine or the length of gestation.
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Table 10
Urine and eluate hCG concentration, specific activity of
urine and eluate and overall recovery of hCG from urine of
hyperemesis patients
urine urine eluate eluate purification overall
hCG snprifir hGG specific factor recovery




































































































IU hCG mg protein
The thyrotropic activity of hCG in women with hyperemesis gravidarum
4.3. Evaluation of the FRTL-5 bioassay system for
measurement of thyrotropic activity of hCG from
pregnancy urine
4.3.a. Effect of urine+- hCG on FRTL-5 cells
There have been no previous reports on the use of FRTL-5 cells to assess
thyrotropic activity of hCG in urine and so before this could be attempted the
effect, if any, of urine on the cells was assessed.
As described in the Materials and Methods section, FRTL-5 cells were incubated
separately with fresh, undialysed, non-pregnancy urine; dialysed, freeze-dried
non-pregnancy urine reconstituted with 5H; dialysed, freeze-dried non-pregnancy
urine with a known amount of hCG added during reconstitution with 5H. After
incubation for 48 hours the ESTA staining method was applied and the results
examined for evidence of inhibition of growth and cell death. Cell death would
result in absorbance readings lower than the blank, ie, lower than the absorbance
given by cells incubated in 5H alone. The results of this study are shown in
Figures 23 and 24.
Cells incubated with undiluted undialysed non-pregnancy urine showed some
evidence of cell death as can be seen from the low absorbance results obtained, but
this could have been due to lack of support medium rather than due to the urine per
se. The same urine diluted in 5H showed no apparent effect on the cells with
regard to cell growth or death. Dialysed, freeze-dried and reconstituted (with 5H)
urine did not appear to significantly affect the cells, and the cells demonstrated a
positive growth signal (increased absorbance using ESTA) when hCG was added
to the urine, implying that the presence of urine did not inhibit the response of the
cells to thyrotropic stimulation by hCG.
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Figure 23
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Figure 24
The effect of dialysed non-pregnancy urine with and
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4.3.b. Dose response curves and potency ratios of bTSH, hTSH,
IRP hCG and partially purified hCG using ESTA
Dose response curves comparing the response of FRTL-5 cells to bTSH, hTSH
and partially purified hCG with both MTT and NYS staining methods are
presented in Figures 25 and 26. These figures demonstrate that bTSH and hTSH
stimulated FRTL-5 cell growth, and that bTSH was a more potent thyrotropic
agent in this system. hCG did stimulate the cells, but the response was much
weaker than that compared to bTSH and to hTSH, with an approximate potency
ratio of 1 mU bTSH: 7 mlU hTSH: 35,000 IU hCG (Table 11).
Dose response curves comparing the response of FRTL-5 cells to partially purifiec
hCG and highly purified hCG with both MTT and NYS staining methods are
shown in Figures 27 and 28. The results show no apparent difference in the
thyrotropic potencies of partially purified and highly purified hCG.
Comparison of MTT and NYS dose response curves to bTSH, hTSH, highly
purified hCG and partially purified hCG are given in Figures 29-32, which are
redrawn from the data present in Figures 25-28. From these, NYS would seem to
be the more sensitive method in that a response distinguishable from the blank was
given at a lower hCG dose than that seen with the MTT stain.
Because of the low sensitivity to hCG (compared to that to TSH), potentiation of
FRTL-5 response to hCG by addition of isomethylybutylxanthine (IBMX), a
phosphodiesterase inhibitor, at 1.8 x 106 mol1 was tried. Results of this study
are shown in Figures 33 and 34 and show that IBMX did potentiate the response,
with an apparent increase in sensitivity in the NYS stain from 100 IU1 xlO 3
hCG to 25 IU1 xl0~3, ie, there was a definite measurable response of the cells to
hCG at a concentration of 25 IU1 xlO-3. The response to 10 IU1 xlO 3 hCG was
not unequivocably different from the zero response (blank) reading although the
mean absorbance was higher than that obtained for the blank.
Comparison of MTT and NYS IBMX-potentiated dose response curves (data
shown in Figures 33 and 34) to partially purified hCG is shown in Figure 35. The
precision of both staining methods was, with some practice in the technique,
good, but the apparent sensitivity differed, with the MTT stain requiring
approximately 100 IU1 xlO3 hCG for a measurable growth signal to be seen,
while the NYS stain showed a measurable response at 25 IU1 xlO-3. This
difference may be explained by the fact that the MTT stain assesses enzyme
activity but had not been optimised and was not done by a reaction rate method.
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Another possibility is thath CG may inhibit the enzyme systems being used in the
MTT staining method.
In all Figures the mean absorbance (x103)+/- 1 sd of three or four wells is shown
for the standards, and test results were obtained by reading the mean absorbance
of the quadruplicate test wells against the IBMX-potentiated NYS hCG
dose-response curve obtained during the same experiment as sample results. All
samples and standards contained the same dose of IBMX (1.6 x 10-6mo1/l) and the
samples were assayed together in one experiment using cells from the same
sub-culture.
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Figure 25
Dose response curves of FRTL-5 response to bTSH, hTSH
and partially purified hCG
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Hormone concentration
bTSH concentrations are in mU1, hTSH concentrations are in mIU1 and hC(
concentrations are in IU1 xlO'3. The vertical bar represents+- 1 sd of
absorbance readings. A is absorbance xlO.
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Figure 26
Dose response curves of FRTL-5 response to bTSH, hTSH
and partially purified hCG
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Hormone concentration
bTSH concentrations are in mU1, hTSH concentrations are in mIU1 and hCG
concentrations are in IU1 xlO3. The vertical bar represents+- 1 sd of 4
absorbance readings. A is absorbance xlO3.
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Figure 27
Dose response curves of FRTL-5 response to highly
purified hCG and partially purified hCG
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Figure 28
Dose response curves of FRTL-5 response to highly
purified hCG and partially purified hCG
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Hormone concentration
hCG concentrations are in IU1 xlO3. The vertical bar represents+- 1 sd of 4
absorbance readings. A is absorbance xlO.
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Figure 29
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absorbance readings. A is absorbance 103.
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Figure 30
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hTSH concentrations are in mIU1. The vertical bar represents+- 1 sd of 4
absorbance readings. A is absorbance xlO.
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Figure 31
Dose response curves of FRTL-5 response to IRP hCG;
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hCG concentrations are in IU1 xlO3. The vertical bar represents+- 1 sd of 4
absorbance readings. A is absorbance xlO.
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Fieure 32
Dose response curves of FRTL-5 response to partially
purified hCG: MTT and NYS comparedI J A A A vu
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Figure 33
Potentiation of FRTL-5 response to partially purified hCG
by addition of IBMX (1.8 x 106 mol1)
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hCG concentrations are in IU1 xlO3. The vertical bar represents+- 1 sd of 4
absorbance readings. A is absorbance xlO3.
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Figure 34
Potentiation of FRTL-5 response to partially purified hCG
by addition of IBMX (1.8 x 106 mol1)
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Figure 35
Dose response curves of FRTL-5 response to partially
purified hCG potentiated by 1.8 x 106 mol1 IBMX;
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Hormone concentration (IBMX added)
hCG concentrations are in IU/I 103.The vertical bar represents+/-1 sd of 4
absorbance readings. A is absorbance 103.
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Table 11
Comparison of approximate relative thyrotropic potencies
of bTSH, hTSH and hCG in the FRTL-5 bioassay
hTKH ml JII hTSH miun hCG IUl 103














1 mU 10 mlU 30,000 IU











1 mU 7 mlU 35,000 IU
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4.3.C. Precision and recovery of FRTL-5 bioassay
Within-plate precision was assessed by running multiple wells of 100 mU1 bTSH
in one microculture plate. Between-plate precision of the bioassay was assessed
by running quadruplicate wells of 100 mU1 bTSH in each microculture plate. In
addition, precision was assessed by running two duplicate patient samples in
quadruplicate on the same microculture plate and the results compared.
Recovery was assessed by using non-pregnant urine to which a known amount
of partially purified hCG had been added (immunoassay result= 395 IU1 xlO).
The spiked urine was dialysed and treated like the patients' samples.
Precision and duplication were good by both staining methods with a within-plate
cv of approximately 2% and a between-plate cv of 3-6%. The reading obtained
for the spiked non-pregnant urine using the NYS method was similar to the
immunological result, but the MTT reading gave a low hCG result.
The results of these studies are shown in Table 12.
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Table 12
Precision and recovery of FRTL-5 bioassay
Precision( 100 mU/1 bTSH
MTT* NYS*
mean A cv mean A cv
n=7Within-plate 205 423 1.5%2.1%
2.9%Between-plate n=12 201 4225.5%
A x103A x103
286+/-5Duplicate sample I. Result 1 69+/- 5
282+/- 6Result 2 70+/-4
309+/- 6130+/-7Duplicate sample 2 Result 1
306+/-5122+/- 9Result 2
Recovery of spiked urine sample( 395 IU/1 x10-3 hCG
Result from hCG MTT dose-response curve= 120 IU/l x 10-3
Result from hCG NYS dose-response curve= 350 IU/l x 103
k Absorbance (A) is shown x 10 J
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4.4. The thyrotropic activity of hCG from women
with hyperemesis gravidarum
Thyrotropic activity of hCG in 16 dialysed, freeze dried urines from women with
hyperemesis gravidarum and 13 dialysed freeze-dried eluates of these urines was
measured using the FRTL-5 bioassay system. The mean of three or four
absorbance results for each sample were translated into IU1 xlO3 of 'apparent
hCG' using a 1.8 x 106 mol1 IBMX-potentiated dose-response curve obtained
with partially purified hCG( Figure 35). The detection limit for the NYS method
was taken to be 20 IU1 xlO; this figure was somewhat abitrary, but a significant
response was seen at 25 IU1 xlO while the response at 10 IU1 xlO was
equivocal, and so it was assumed that the actual sensitivity limit of the assay lay
between these two values. Any sample giving an equivalent absorbance reading
below that equivalent to 20 IU1 xlO on the dose-response curve was reported to
have no detectable apparent hCG. Because of the apparent higher sensitivity of
the NYS staining method compared to the MTT method, and to the better precision
and recovery results, only the NYS results were used.
The 'apparent hCG' was correlated with the immunologieally-active hCG, which
had been measured using the Hybritech EIA for dimer hCG( Appendix 3), and
an 'apparent' to measured( AM) hCG ratio obtained for each urine and eluate
sample, provided there had been a detectable response in the bioassay. The hCG
result was also used to calculate a 'hTSH-like activity' result using the potency
ratio of 5,000 IU hCG: 1 mlU hTSH (see Table 11). 5 urines gave no detectable
response in the bioassay; 3 of these urines had eluates which also gave no
response, but the remaining 2 urines had no eluate sample. All 5 'no-response'
urines came from women with normal serum T4 levels. There were two additional
eluate samples which gave no response in the bioassay, and both of these came
from women with normal serum T4 levels, although the urine of one of these
patients showed measurable thyrotropic activity. The immunologically- reactive
hCG concentrations of the 'no-response' samples were quite low, being in the
range 1 33 IU1 xlO3 and the fact that no response was detected may simply be a
function of this, however, other samples with low hCG content showed
considerable response in the bioassay. Table 13 shows the serum T4 and TSH
levels and the sample hCG content of the samples as well as the response of the
FRTL-5 cells to these samples expressed in terms of 'apparent hCG' and
'hTSH-like activity'. Figures 36 and 37 show the thyrotropic response of the
1 some samples were lost in transit from Hong Kong to UK and could not be replaced
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samples expressed as IU/1 x10 -3 of 'apparent hCG' compared to their
immunologically measured hCG content.
The results of this study show that different patients had different A/M hCG
ratios, ie, that their urine and eluate samples contained hCG of variable thyrotropic
potency. All urine and eluate samples from patients with high serum T4 levels
gave a measurable response in the bioassay, although the A/M hCG ratios varied
widely between different patients and did not correlate with absolute values for
serum T4 or TSH.
The A/M hCG ratio, ie the thyrotropic potency of hCG, of the urine and eluate
samples and the A/M hCG ratio multiplied by the serum hCG concentration, ie the
combination of potency and quantity, or total circulating thyrotropic activity of
hCG, were related to serum T4 and TSH concentrations and to the length of
gestation in those patients for whom data was available. After allowing for
possible differences in urine concentration by dividing by the urine creatinine
concentration, this 'hTSH-like activity' was also related to the serum T4 and TSH
levels and to the length of gestation. The results are presented in Figures 38- 43
and Tables 14 and 15. The statistical tests used to discern possible differences
between the groups (high and normal T4, normal and low TSH and early and
mid- gestation) groups were the unpaired Student's t-test where the number of
results obtained was acceptably high (>40) and the Mann-Whitney non-parametric
rank sum test for those variables with few (<10) results. The results show that
serum hCG levels were significantly higher in those patients with high T4 and/or
low TSH, but no other significant differences were found. The urine and eluate
samples with the highest 'hTSH-like activity' (>2 mIU/umol creatinine) came
from a patient with low serum TSH and high serum T4, however, equally low
TSH and high T4 values were found in patients whose samples had very low
'hTSH-like activity' and no overall significant correlation was found.
The highest total circulating thyrotropic activities of hCG (409 IU/1 x10-3 for
urine and 2133 IU/l x103 for eluate) came from patients with normal serum T4
levels of 116 and 132 nmol/l respectively. There does not therefore seem to be
any straightforward relationship between serum T4 and the putatative total
circulating thyrotropic activity of hCG.
Differences in gestational age also showed no relationship with the thyrotropic
quality of hCG, the 'hTSH-like activity' of the sample or the total circulating
thyrotropic activity of hCG, although the 3 highest eluate A/M hCG ratios came
from women in early pregnancy (9, 9 and 11 weeks gestation).
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Table 13
FRTL-5 bioassay results on urine and eluate samples and
associated thyroid function results
Sample Urine Samples Eluate Samples Serum Samples
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AhCG= apparent hCG by bioassay
hTSH-likeactivity= hCG content5000creatinine concentration of original urine
sample umolll (5000= potency ratio ofhTSH. hCG in bioassay on mIU:IU basis)
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Figure 36
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Figure 37
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Figure 38
Relationship between serum T4 concentration and the
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Figure 39
Relationship between serum TSH concentration and the
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Figure 40
Relationship between length of gestation and the
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Figure 41
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Figure 42













10 100 1000 10000
A/M hCG x Serum hCG IU/I x10 -3
125The thyrotropic activity of hCG in women with hyperemesis gravidarum
Figure 43
Relationship between the length of gestation and total
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Table 14

















































Urine AM hCG 6.8 5 5.3 6 n.s.
Urine AM hCG
x serum hCG 5.5 4 4.6 5 n.s.
Eluate AM hCG 4.5 3 4.5 5
n.s.
Eluate AM hCG
x serum hCG 4.0 2 3.2 4
n.s.
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Table 15
Comparison of variables in hyperemetic women with low




































Urine AM hCG 4.9 4 5.1 5 n.s.
Urine AM hCG
x serum hCG 5.0 4 5.0 5 n.s.
Eluate AM hCG 2.7 3 4.3 3
n.s.
Eluate AM hCG
x serum hCG 2.7 3 . 3 3
n.s.
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Table 16













152 96 31 94 67 16 0.05
0.38 .50 31 0.51 .34 17 n.s.
serum T4 fnmol11 137 51 33 152 51 16 n.s.











urine AM hCG 4.9 7 6.8 3
n.s.
urine AM hCC
x serum hCG 3.8 5 5.7 3
n.s.
eluate AM hCG 4.0 6 4.0 1
n.s.
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4.5. Isoelectricfocusing and immunoblotting of hCG
In all, 10 acrylamide gels were run and varying concentrations of urine and
anti-hCG were tried, however isoelectricfocusing of diluted, neat and concentrated
(x5) urines was disappointing, with no hCG bands being seen. The first antibody
( rabbit anti-hCG beta) in varying dilutions between 1/100 and 1/3 showed no
improvement in the sensitivity. Isoelectricfocusing of urine concentrated more than
5 times caused burning of the gel, presumably due to the high salt concentration.
The urine samples were therefore desalted and re-concentrated approximately x30
and isoelectricfocusing performed again. Partially purified hCG (Sigma)
concentrated to approximately 10,000 IU/1 x10-3 was subjected to the entire
procedure of concentration, isoelectricfocusing, transfer onto nitrocellulose and
immunoelectroendosmosis and several bands were clearly seen, implying that the
various procedures were being carried out correctly but that either the sensitivity of
the antisera was poor or that the hCG from the samples was not being drawn into the
gel.
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4.6. Pregnancy outcome with reference to the sex of the
baby
It has previously been reported that hyperemesis patients have a higher than expected
number of female babies (112,134). The reason for this is not known, although it
has been suggested that testosterone production by the male foetus overcomes the
nausea-inducing effect of oestrogens and so may prevent hyperemesis in the
mother. hCG levels in the first and second trimesters measured in women with a
male foetus showed no significant difference to those in women with a female foetus
(189).
Of the 58 women involved in this project, pregnancy outcome with regard to sex of
the baby is known in 28: 10 of the babies were male and 18 were female. Figures
obtained from the Hong Kong Medical and Health Department Information Services
Section show that over the two year period 1988-89 the numbers of male and female
babies born were 73,932 and 69,250 respectively, or 51.6% male, 48.4% female.
The ratio of male to female babies born to the hyperemesis patients involved in this
study is therefore different from the general population, but not significantly so
(chi-squared test). The preponderance of females may become significant if larger
numbers could be obtained, and follow-up studies of the women yet to be delivered
will be made.
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5.1. Introduction
This project was designed to investigate possible differences in the thyrotropic
activity of hCG from women with hyperemesis gravidarum and to explore the
relationship, if any, between the thyrotropic activity of hCG and thyroid function
in these women. The thyrotropic activity of hCG was measured using an FRTL-5
bioassay system and an innovative response signal termed ESTA, which had not
previously been used for this purpose.
In this section, the limitations of the study and assumptions made will be
discussed and the results presented in the previous chapter will be discussed in
relation to previously published findings regarding thyroid function and hCG
levels in hyperemesis gravidarum and the thyrotropic activity of hCG. Finally, the
application of the FRTL-5/ESTA bioassay system will be discussed and general
conclusions with reference to the hypothesis and suggestions for further work will
be given.
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5.2. Assumptions made and limitations of the study
This study was subject to several limitations, some of which were known in
advance but unavoidable, others arising during the project due to lack of time,
resources and facilites. In addition, some assumptions had to be made regarding
various aspects of the project work and the methodologies used. These
assumptions and the limitations of the study are outlined below.
Nature of sample:
It is recognised that urinary hCG may not reflect circulating hCG in terms of
biological activity and that there may be present in urine factors which may
interfere with the bioassay for thyrotropic activity. However, for the purposes of
this project, it was assumed that if urine and/or eluate contained thyrotropic
activity, this could be attributed to the hCG in the sample and that the thyrotropic
activity of urinary and circulating hCG( from the same patient) would be the
similar.
Loss of thyrotropic activity during freeze-drying, storage and reconstitution of
samples:
It was not possible to measure the immunologically active hCG after reconstitution
but before bioassay for measurement of thyrotropic activity. The measurement of
immunologically active hCG was made after dialysis, and it was assumed that
during the processes of freeze-drying, storage and reconstitution, there would be
no loss of immunological or biological activity, or at least a similar loss in all
samples.
hCG measurement:
hCG was quantitated using an enzyme-linked immunometric method which is
claimed to be specific for dimer hCG free subunits should not be detected and it
was assumed that results obtained by this method would accurately reflect the
content of biologically active dimer hCG in the sample.
Number of samples:
E-lyperemesis gravidarum is not a common condition and, since the urine sample
collection period would be limited to approximately one year, the number of urine
samples aimed at for this study was therefore quite small- 20 hyperemesis and 20
controls being the target numbers set.
At the time of bioassay, when no turther unnes couta be processes, 17 suitaoie
urine samples from hyperemesis patients had been received. However, control
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samples proved very difficult to obtain. Due to a late booking system operated in
Hong Kong, normal pregnant women in early pregnancy, the time of interest for
this study, do not present to hospital clinics. By the time the women routinely
attend ante-natal clinics their pregnancies are well advanced, excluding them from
this study as their gestational ages would not match the hyperemesis patients'. 3
control urines were obtained from healthy, apparently normal colleagues in early
pregnancy, but no blood could be obtained. 4 additional 'control' urines were
obtained from women on an in-vitro fertilisation programme, however, these
probably cannot be regarded as true controls due to their special circumstances,
and to the fact that 3 of these 4 patient were thyrotoxic. The problem of controls
proved insurmountable, and the number of 'control' urines remained at 7.
Consequently, no valid comparison between normal and hyperemetic women
could be made and the results of the 'control' samples are not included in the
Results section.
Purification methods:
The methods chosen to isolate and purify urinary hCG employed well-established
techniques such as gel-filtration, ion-exchange and affinity chromatography. Each
part of the purification procedure was set up specifically for this project and thus
had to be modified to suit the available resources and needs of the project, after
which calibration and recovery procedures had to be undertaken. The overall
purification procedure is not intended to be seen as the ideal or definitive way in
which hCG should be purified, but was chosen as the most suitable for this
project with regard to previous experience, type of sample, and the time and
resources available.
Bioassay for thyrotropic activity:
FRTL-5 cells are of rat origin. For the purpose of this study it was assumed that a
positive growth response by these cells was reflecting thyrotropic stimulation by
the test substance and that this thyrotropic activity would also be present in human
thyroid tissue in vivo.
The aim of this project was to measure the thyrotropic activity of hCG in women
with hyperemesis gravidarum in order to test the hypothesis that hCG induces the
thyroid disturbances often seen in these patients. It was not within the scope of
this project to account for such differences by way of, for example, amino acid
analysis, nor could the primary biological activity ofhCG (the luteinising activity)
be compared with the secondary, thyrotropic activity. In addition, as no suitable
human thyroid cell-line exists and because serum inhibits the FRTL-5 cells, the
assumptions made with regard to FRTL-5 response= human response and urine
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hCG= circulating hCG, could not be supported by experimental work
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5.3. Thyroid function in hyperemesis gravidarum and the
role of hCG in the aetiology of pregnancy-associated
hyperthyroxinaemia and hyperemesis gravidarum
Relationship between quantity of hCG and thyroid function in hyperemesis
gravidarwn
The results obtained in this study show a significant correlation between the serum
levels of hCG and T4 (r= 0.27, P0.05) and a significant inverse correlation
between serum levels of hCG and TSH (r=0.45, P<0.001). It has been shown
previously (40) that free thyroxine levels correlate well with total T4 and that the
increase in T4 in hyperemetic women cannot be accounted for by increased
thyroxine binding globulin. Evidence of thyroid overstimulation in hyperemesis
gravidarum is supported by the finding of low serum TSH levels in approximately
half (47%) the patients studied, a finding not previously reported. Additionally,
since several patients had low TSH but normal T4, there may have been a relative
increase in the serum T4 in most, if not all, of the patients, ie, each individual
patient may have had some degree of thyroid overstimulation leading to a relative
increase in serum T4, even though the absolute value remained within the
reference interval.
The results of this study have, therefore, confirmed and extended the findings of
others which revealed disturbed thyroid function in a large proportion of
hyperemetic women and that this may be related to hCG production
(36,39,40,135,170). 7 (12%) of the patients had very high serum hCG levels of
200 IU/1 x10-3 4 of these women had elevated but 3 had normal T4 levels,
including the patient with the highest serum hCG( 422 IU/1 x10-3). This conflicts
somewhat with the findings of Norman (38) who reported that, in a study of
women with gestational trophoblastic disease, every patient who had a serum hCG
of 300 IU/1 x10-3 and above was thyrotoxic. The reason why some women in
this study had normal serum T4 in association with very high hCG levels may be
that the production of hCG had increased suddenly, and the thyroid had not yet
responded to the extra thyrotropic stimulation at the time of sampling, that there
had been a relative increase in serum T4 due to hCG-induced thyroid stimulation
but that the increase had not been sufficient to take the T4 level above the upper
limit of the reference interval, that the hCG being produced by these women was
relatively less thyrotropic or that hCG per se is not the thyrotropic agent in any of
the women studied, but is merely co-incidentally high in some hyperthyroxinaemic
hyperemetic women. Some workers have cast doubt on hCG being a thyrotropic
stimulator, as thyrotoxicosis or hyperthyroxinaemia has not been reported in men
with hCG-producing malignancies even though the serum hCG in these patients
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was grossly elevated (172). It is known that hCG produced abnormally, ie in
situations other than pregnancy, may be biologically less active (45,46,48-54,59),
but if hCG has significant thyrotropic activity it may be expected that gross
production of even a less active form would cause some degree of thyroid
over-stimulation.
Serum T4 and TSH levels of the patients studied were, as expected, inversely
correlated (n= 55, r= 0.41, P<0.01), however, when T4 and TSH were
correlated with the effect of hCG held constant the correlation was not significant.
This may imply some role for hCG in determining T4 levels in these women,
although the relationship is not clear. Individual women with high serum T4 had
hCG levels comparable to or lower than other patients whose T4 was normal,
while others with relatively high hCG had no evidence of thyrotoxicosis. TSH
levels were low or towards the lower end of the reference interval in all patients
except one, and this patient also showed a relatively low hCG level. The
correlation between increasing hCG and decreasing TSH in the group was strong,
but higher hCG did not necessarily mean lower TSH (or higher T4) in the
individual, implying possible individual differences in the ability of hCG to
stimulate the thyroid and, thereby, to inhibit TSH secretion.
There does, therefore, appear to be some relationship between the quantity of hCG
produced (serum hCG concentration) and thyroid function in hyperemesis
gravidarum, but this does not appear to be a straightforward relationship in that,
while the hyperthyroxinaemic patients and those with low serum TS H had higher
serum hCG levels as a group, there were individual patients with high hCG who
remained euthyroid and other patients with relatively modest hCG levels had
hyperthyroxinaemia. This may imply an individually-determined response to
hCG, perhaps because of variation in the thyrotropic activity of the hCG being
produced by the individual.
Relationship between potency of hCG and thyroid function
There was no significant correlation between T4 or TSH and the A/M hCG ratio or
the 'hTSH-like activity' for either urine or eluate samples, although sample
numbers were low and individual patients samples showed wide variation with
some samples giving no detectable thyrotropic stimulation in the bioassay used.
Individual patients with high serum T4 levels had comparable A/M hCG ratios and
'hTSH-like activity' with euthyroid patients, and patients with the lowest serum
TSH levels did not necessarily have the highest hCG thyrotropic potency indices.
Measurable thyrotropic activity was found in all samples from patients with high
m T4 while n response was obtained on samples from 5 patients with
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normal T4, however this apparent difference may be due to absolute differences in
quantity of hCG in the samples rather than in relative thyrotropic activity
differences as the no-response samples contained low amounts of hCG.
An acidic variant of hCG with much increased thyrotropic activity has been
reported (19) in a patient with trophoblastic tumour. This was not detectable in the
serum of normal pregnant women but it is possible that individual women produce
variable quantities of this (or another) variant and so have individually varying
thyrotropic activity in their serum due to hCG. The results obtained in this study
would support the theory that the thyrotropic activity of hCG is variable between
and, perhaps, within individuals. There are, however, important flaws in this
project, including the low sensitivity to hCG of the bioassay used to measure the
thyrotropic activity of the patients' samples and the small number of samples
examined. The samples which gave the highest relative thyrotropic activity all had
a low hCG content as revealed by immunoassay, and the thyrotropic stimulation
measurements of these samples were often on the lower limit of the sensitivity of
the bioassay. Samples of higher immunologically-reactive hCG content had
relatively lower, but variable, thyrotropic activity, but the small sample numbers
make it difficult to come to a conclusion.
If the bioassay results are accepted as a valid approximation of thyrotropic activity
then they may imply that higher production of hCG is associated with productior.
of hCG of lower biological activity in terms of thyrotropic activity and, possibly,
also the primary biological activity of luteinisation. This could indicate the
presence of a feedback mechanism which controls the overall activity of hCG in
terms of combined quantity and potency. Wide and Hobson (81) compared the
primary biological activity of hCG (measuring uterine weight gain in immature
mice) with the immunologically-active content (B/I ratio) of hCG in the serum of
pregnant women in early and late pregnancy, and examination of their results
shows there was a decrease in the biological to immunological ratio as hCG
production increased during the first trimester. Ranta (82), using an in vitro
bioassay, a radioreceptor assay and a fluoroimmunoassay for hCG, showed that
individual women had different B/I ratios, varying from 0.75- 2.73. These
results could be interpreted to further support the theory that different women
produce variable quantities of biologically more (or less) active hCG. This could
help explain why the range of hCG levels seen between different women at the
same stage of pregnancy is so wide.
Relationship between the total thyrotropic activity of hCG and thyroid function
There was no significant correlation between serum T4 or TSH levels and the A/M
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hCG ratio multiplied by the serum hCG concentration, or total circulating
thyrotropic activity. Individual patients had comparable T4 and TSH levels with
total circulating thyrotropic activity of hCG varying over the range of
approximately 20- 2,000. Those patients with the highest serum T4 levels did not
have the highest total circulating thyrotropic activity levels while the two patients
with the lowest total activity had elevated T4 levels. These results do not support
the theory that the combination of increased thyrotropic potency and absolute
quantity of hCG is related to hyperthyroxinaemia, but sample numbers were small
and interpretation of the results must take this into account. It is also possible that
the high T4 found in some patients was a reflection of the potency and/or quantity
of hCG in the circulation a few days before sample collection, and therefore that
the thyrotropic activity of the hCG in the collected sample and/or the serum hCG
level was not related to the patient's thyroid status at that time. The half-life of
hCG in the circulation is 12-36 hours but it is not known if large differences in
production or metabolic clearance rates occur from day-to-day. Such differences
could result in large variation in serum hCG concentrations over a period of a few
days and this could in turn lead to rapidly changing serum T4 levels.
Relationship between hyperemesis gravidarum and serum hCG
Because of the unforseen problem of lack of samples from suitable control
patients, there are no appropriate results with which to address this possible
relationship. 7 'control' samples, comprising 3 normal pregnant women and 4
pregnant women from an in-vitro fertilisation (IVF) clinic, donated urine, but the
serum hCG, T4 and TSH results were not available on most. 3 of the 4 IVF
patients were thyrotoxic, but no infomation regarding their degree of nausea and
vomiting was obtained, although they were not hyperemetic. One of the normal
pregnant women from whom no blood was obtained had morning sickness
described as 'severe': this patient, incidentally or otherwise, had a very high
urinary hCG concentration (500 IU/l x10-3) and, since the serum and urine hCG
levels of the other project patients for whom both results were available correlated
well presumably a concomitantly high serum hCG. Neither her urine or eluate
sample had a high A/M hCG ratio.
hCG levels in the serum of the patients covered a wide range (1-422 IU/l x10-3).
hCG production in hyperemesis gravidarum has been reported to be higher than
that in normal pregnancy, although this has been disputed (6,115). Comparing
the serum hCG levels of the hyperemetic project patients with those previously
published for normal gestation, the hyperemetic women studied in this project
seem- to have considerably higher hCG levels. Braunstein (3) found a peak hCG
concentration of around 50 IU/1 x10-3, but 37 (64%) of the patients in this study
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were found to have serum hCG > 100 IU/1 x10-3, while 7 (12%) had levels 200
IU/1 x10-3. However, the apparently higher levels found in many of the project
patients as compared to generally accepted, previously published results may
simply be an indication that a more up-to-date study of hCG production in normal
pregnancy is needed, rather than a true indication of excessive hCG production in
hyperemesis gravidarum.
Relationship between gestation and hCG quantity, potency and total circulating
thyrotropic activity
Serum hCG levels in early (_12 weeks gestation) were significantly higher than in
later (12 weeks gestation) pregnancy. The A/M hCG ratios taken as a group
tended to be lower, although not significantly so, in early pregnancy, but the 3
highest eluate A/M hCG ratios were found in women in the first trimester of
pregnancy. This possible combination of lower potency with higher quantity of
hCG resulted in no apparent change in the total circulating thyrotropic activity of
hCG during the period of gestation studied (6- 24 weeks), but numbers were
small and there were large individual differences, eg, one of the highest urine A/M
hCG ratios was in a women whose gestational age was 17 weeks, but the urine
from another patient of the same gestational age gave no measurable response in
the bioassay.
Hyperemesis gravidarum is a condition which develops during the first trimester
and resolves in later pregnancy, and pregnancy-associated hyperthyroxinaemia is
also a condition which develops in the earlier stages of pregnancy and
spontaneously resolves as the pregnancy advances. The apparent non-relationship
between thyrotropic activity of hCG and length of gestation implies that the
thyrotropic activity of hCG, either per se or in combination with the amount of
hCG in the circulation at the time, is either one of individually determined
variation, regardless of gestation, or has no causal role in the development of
hyperemesis gravidarum or pregnancy-associated hyperthyroxinaemia.
Relationship between isoelectric point differences and thyrotropic activity of hCG
The isoelectricfocusing and immunoblotting aspect of the project was an additional
one which was attempted to try to resolve the problems of small sample numbers
and large variation in the bioassay results. It was hoped that that those women
with high serum T4 would exhibit a different pattern of hCG using this technique,
and that the different bands seen could, hypothetically, be more thyrotropic forms
of hCG responsible for the hyperthyroxinaemia in these patients.
Unfortunately, no results are available at this time due to technical difficulties with
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the method. Only samples with very high (>4,000 IU/l x10-3) concentrations of
hCG could be visualised, and the project urine samples used, even after
considerable concentration, did not approach this level. The sensitivity increased
when the sample application time was increased from 30 minutes to almost two
hours, after which the pattern of hCG at 1,000 IU/I x10-3 could be detected,
however the samples showed a large amount of tailing, and this, together with the
poorer than expected sensitivity, implies that hCG is not being successfully drawn
into the gel. Previous studies (19,48,49,53,55) employing isoelectricfocusing of
hCG have used either dissociated hCG or have used gel rods rather than gel slabs
and focused for a much longer time. Free subunits are smaller and presumably
can penetrate the gel more easily. Sample application to a rod is more direct and
the sample size much larger, which may explain the reported success of this
technique.
It is possible that hCG is being repulsed from the acrylamide gel, perhaps by the
ampholines, or it may remain adsorbed to the filter paper applicator. Alternatively,
the temperature chosen to run the gel (10°C) may be changing the configuration
of the molecule so that it cannot physically penetrate the gel. To resolve these
questions and, hopefully, to gain some meaningful results on the type of hCG
being produced by hyperemetic women with and without high serum T4 levels,
studies using different types of sample application, different sample application
times and temperatures and using agarose instead of acrylamide gel would be
useful. A preliminary study using agarose has shown improved sensitivity, with
the pattern of hCG at <500 IU/l x10 -3 visualised, but the technique requires
modification to improve resolution of the different fractions.
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5.4. The evaluation and application of the FRTL-5
bioassay system and, E S T A for measuring the
thyrotropic activity of hCG in urine and extracts of
urine
The FRTL-5 cells appear to be quite robust and were not deleteriously affected by
required to give a significant, measurable response. The dose response curves of
bTSH, hTSH and hCG appeared parallel using both staining methods and the
maximum response was obtained with similar doses of bTSH and hTSH,
although the maximum response obtained was higher with bTSH. At the highest
dose of hCG used( 500 IU/l x 10-3) neither stain showed a maximum response.
Human thyroid tissue has been reported to have high affinity, low capacity
receptors and low affinity, high capacity receptors (193). It is not known if the
FTRL-5 cells have these two populations of receptors, but it is possible to
speculate that the difference in the potencies of bTSH, hTSH and hCG reflect
differences in their affinities for the high- and low- affinity receptors. To emulate
the thyrotropic stimulation afforded by 1 mU of bTSH, approximately 35,000 IU
of hCG were required, ie, on a milliunit bTSH to IU of hCG basis, there was a
potency ratio of approximately 35,000. hTSH was less potent than bTSH in the
bioassay system, with a relative potency ratio of 1 mU bTSH: 7 mIU hTSH. The
apparent parallelism of response to the different hormones may indicate that the
effectiveness of the low affinity receptor in terms of triggering post-receptor
response is similar to that of the high affinity receptor but that maximal stimulation
is less and that higher 'triggering' doses are required. If FRTL-5 cells have only
one type of receptor then the results would imply that the different hormones have
different affinities for the receptor and/or that the hormones have different efficacy
in triggering the post-receptor response.
The ESTA system proved to be technically simple and precise, but the MTT
staining method seemed less sensitive than the NYS staining method. Both these
staining methods assess growth of the cells, but the methods were not optimised,
and if this was done the sensitivity of the MTT method may increase to match that
of the more straightforward NYS staining method. Alternatively, the large doses
of hCG required to stimulate the cells may inhibit the enzyme systems involved in
the MTT staining method, as the sensitivity towards preparations of TSH appears
similar for the two staining methods. Addition of 1.8 x 10 -6 mol/I IBMX, a
phosphodiesterase inhibitor, potentiated the response of the cells to hCG. There
have been previous reports of increased sensitivity of the FRTL-5 bioassay system
to thyrotropic agents after addition of IBMX (20,180,184), but the amount of
dialysed urine, however, the sensitivity to hCG is low and very high doses were
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IBMX is not standardised. 1.8 x 10-6 moll was chosen for the final
dose-response curves and sample measurements as results a smaller dose did not
result in a demonstrable higher response. 1.8 x 10-6 moll did augment the
sensitivity to a level at which measurable response of the cells could be seen at 25
IU/1 x10-3 hCG (NYS stain) and so allowed results to be obtained on most of the
project samples. This degree of sensitivity matches or supercedes those
previously reported for hCG using the FRTL-5 cells and employing the more
technically demanding and expensive response signals of cAMP or iodide uptake
measurements. However, the MTT response signal remained poor and some
samples showed no measurable response in the NYS response signal. It is
possible that a higher concentration of IBMX would have further increased the
sensitivity with no adverse effects on the cells, but no time was available to do
such a study. Alteratively forskolin, an adenylate cyclase activator, could be used
to increase the sensitivity. This has been used in the past to potentiate response of
the FRTL-5 cells to bTSH, hTSH and thyroid stimulating antibodies (180, 184)
and there is a recent report (194) of a forskolin-potentiated cAMP response of the
cells to hCG at 15 IU/1 x10-3.
The FRTL-5 bioassay system and the ESTA staining method used in this study
have been shown to offer a practicable and precise method for measuring the
thyrotropic activity of hCG in urine and extracts of urine, and a further increase in
sensitivity of the test is possible by employing a higher dose of IBMX and/or
forskolin and by optimising the ESTA staining methods used. High doses of
hCG, whether partially or highly purified, and urine of high hCG content
unequivocably stimulated growth of the cells and this supports and confirm
previous findings that hCG has thyrotropic activity (13,14,15,17,18,117,122).
However, potency ratios found in the bioassay used were different from those
previously reported which have varied from 2,000 to 42,000 using various
preparations of hCG and different bioassay systems (18,19,21,115). This
variation is likely to be due to inter-species receptor differences and it must be
remembered that the bioassay used here employed rat tissue and a response system
which has not yet been calibrated against or compared directly to response in
human thyroid tissue.
Amir and co-workers (16,66,117,195) have consistently reported that purified
hCG does not stimulate human thyroid tissue, while contaminants and desialylated
hCG confer apparent thyrotropic activity on crude preparations of hCG.
However, these studies have not been confirmed by other workers, who have
reported significant thyrotropic activity in various preparations of hCG using
response in rat, bovine as well as human thyroid tissue. The thyrotropic activity
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of hCG has been reported by these workers to increase as the purity increases and
to be removed by addition of anti-hCG to the hCG preparation, results that
indicate that it is hCG itself which is the thyroid stimulator. Using the FRTL-5
system, the results obtained in this project indicate that hCG has significant
thyrotropic activity, albeit some 35,000 times and 5,000 times less than that
exhibited by bTSH and hTSH respectively. Highly purified hCG and partially
purified hCG showed similar potencies which, if the thyrotropic activity was
truely due to hCG, is to be expected. From the thyrotropic potency of hCG found
in this project we can calculate that approximately 25 IU/1 x10-3 hCG in serum is
equivalent to 5 mIU/1 hTSH, which is the upper limit of the reference interval.
Most patients had serum hCG levels well above this, but only 38% had evidence
of increased serum T4. This casts doubt on hCG itself being the thyrotropic agent,
as one would expect that all women with serum hCG above a certain level would
have hyperthyroxinaemia and, while some do, one patient with a serum hCG of
>400 IU/1 x10-3, which is theoretically equivalent to a TSH level of almost 100
mIU/l, had a normal serum T4 of 73 nmol/l. If the bioassay could be made more
sensitive it may be possible to perform individual dose-response curves for hCG
from individual patients, and in this way further explore the finding that the
thyrotropic powers of hCG differ among individual women, or that the thyrotropic
agent is a contaminant, produced during pregnancy and similar to hCG in its
physico-chemico characteristics, but a separate substance. It should also be noted
that one of the assumptions for the purposes of this project was that urine hCG
was equivalent to serum hCG and that thyrotropic activity of one would be the
same as the other. This is not necessarily the case, and the wide variation in the
apparent thyrotropic activity of hCG in the patients' samples may simply be due to
varying quantities of biologically active, intact dimer hCG and equally varying
quantites of immunologically-reactive but biologically inactive fragments. Serum
has been reported to inhibit the FRTL-5 cells (177), but if the thyrotropic activity
of hCG in serum could be measured then more valid results may be obtained.
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5.5. General conclusions with reference to the hypothesis
and suggestions for further work
The hypothesis being tested by this project is that women with hyperemesis
gravidarum have disturbed thyroid function due to hCG, more hCG per se, a more
thyrotropic form or a combination of both.
From the results obtained it would seem that disturbed thyroid function commonly
occurs in hyperemesis gravidarum, with 38% of the patients in this study having
serum T4 levels above the upper limit of the non-pregnant reference interval and
47% of the patients having low serum TSH levels. This agrees with previous
reports of one third or more hyperemetic women having hyperthyroxinaemia, but,
since most hyperemetic women in this and other studies are euthyroid, it is
unlikely that thyroid function and hyperemesis gravidarum have a direct causal
and/or consequential relationship in most hyperemetic patients. Serum T4 and
hCG levels were found to have a significant correlation, and hCG levels in many
of the patients with hyperemesis gravidarum were found to be much higher than
previously published levels found at particular stages of gestation, however,
individual variation was wide and high hCG was not necessarily associated with
hyperthyroxinaemia. The thyrotropic activity of hCG in the urine of hyperemetic
women showed wide variation and no apparent relationship to thyroid function
could be established. When the amount of hCG in the circulation was taken in
conjuction with the thyrotropic potency of their hCG, those women with high
values of total circulating thyrotropic activity of hCG did not necessarily have
elevated T4, but TSH levels in these women were all low, implying that
something other than TSH may have caused a relative increase in T4 and thus
inhibited TSH secretion, even though the serum T4 level remained within the
reference interval.
Without the benefit of larger samples numbers and/or a longitudinal study to
follow changes in the individual patient's quantity and potency of hCG and
thyroid function, the postulation that hyperemetic women in general have
disturbed thyroid function has not been confirmed. A significant proportion of
hyperemetic women undoubtedly exhibit elevated serum T4 levels, but so too do
normal pregnant women and the incidence of pregnancy-associated
hyperthyroxinaemia may be more common than previously thought. The
postulation that hyperemetic women produce more hCG per se has been supported
in part by this study, in that the serum hCG levels of the patients studied here
appear to be much higher than those previously published for normal pregnancy,
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but an up-to-date study of hCG production in normal gestation is required to
confirm this. This study has shown that the thyrotropic activity of hCG from
urine can be measured using the FRTL-5 bioassay system and the ESTA response
signal and that the relative thyrotropic activity of hCG from different women is
different. However, the postulation that hyperemetic women in general produce a
more thyrotropic form of hCG has not been supported, and, although the apparent
thyrotropic activity of the different samples showed wide variation, there was no
significant relationship between the serum T4 and either the thyrotropic potency of
hCG or the total circulating thyrotropic activity of hCG in this condition.
However, sample numbers were small and the bioassay used lacked sensitivity in
the hCG concentration range of many of the samples individual patients with
high T4 did have hCG of apparently high thyrotropic quality, while in others high
T4 was found in association with very high serum hCG levels. It cannot be ruled
out, therefore, that, while no significant relationship was found in the hyperemetic
women as a group, individual women may produce a more thyrotropic form of
hCG or more hCG per se and that this may contribute to the development of
transient pregnancy-associated hyperthyroxinaemia and, perhaps, to the
multi-factorial aetiology of hyperemesis gravidarum.
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5.6. Summary
In conclusion, the results of this study indicate that the FRTL-5 bioassay systerr
and the ESTA response signal are suitable for use in the measurement of the
thyrotropic activity of hCG in urine and extracts of urine, although improved
sensitivity is desired. This may be possible if a higher concentration than 1.8 x
10-6 moll of the phosphodiesterase inhibitor IBMX is used and/or if the adenylate
cyclase activator forskolin is employed. Using this bioassay system, the
thyrotropic activity of hCG from urine of women with hyperemesis gravidarurr
has been found to vary between individuals, but, possibly due to the small
numbers tested, no relationship could be established between the thyrotropic
activity of hCG and thyroid function in hyperemesis gravidarum. In addition,
hCG levels in the serum of hyperemetic women have been found to significantly
correlate with serum T4 and TSH levels, with an increased hCG being associated
with elevated T4 and decreased TSH levels. There were, however, individual
women with hyperthyroxinaemia whose serum hCG levels were relatively modest
for gestation, while a normal serum T4 level was found in a patient with a very
high hCG level of 422 IU/1 x10-3. The relationship between hCG and thyroid
function therefore appears to be one of individual determination, ie, it would
appear that the thyrotropic activity of hCG varies between and, perhaps, within
individual women, and this may be due to one or more of the following factors:
1 that, while hCG is weakly thyrotropic, it is a variant of hCG, rather
than hCG per se, which is the thyrotropic agent responsible for
pregnancy-associated hyperthyroxinaemia this variation may be
due to amino acid substitution, in the degree of sialylation of hCG
or may be due to in vivo removal of the CTP the variation may
cause direct increase in thyrotropic activity of hCG or an indirect
increase by extending the half-life of circulating hCG in the plasma
hCG is thyrotropic only in the correct hormonal/biochemical2
environment
If the variation in thyrotropic potency of hCG is due to sialic acid or amino acid
substitution then this should become apparent in isoelectricfocusing/
immunoblotting studies before and after desialylation by neuraminidase, and a
longitudinal study correlating changes in quantity of hCG, thyrotropic potency of
hCG and thyroid function would help resolve the still problematical and
hypothetical relationship between hCG, thyroid function and hyperemesis
gravidarum.
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Appendix 1
Regeneration of Concanavilin A Sepaharose
After elution of adsorbed glycoproteins with 0.5 mol/1 alpha methylmannoside, the
Con A was regenerated for further use as follows:
1 wash with 10 volumes of Tris/HCl buffer, 0.1 moll, pH 8.5, allow to settle,
decant
2 wash with' 10 volumes of 0.1 mol/l acetate buffer in 0.5 mol/1 NaCl, pH 4.5,
allow to settle, decant
3 wash with 10 volumes of 0.05 moll phosphate buffer in 0.5mol/l NaCl, pH 7.2
(PBS starting buffer), allow to settle, decant
4 mix with original buffer and store at 4°C until preparation for use as 50%
solution in PBS starting buffer.
Effectiveness of regenerated Con A was checked by carrying out adsorption and
elution of a known amount of hCG using new and regenerated Con A in tandem.
The results obtained were comparable, the relative recoveries being within 6%.
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Appendix 2
Buffer exchange and concentration
After elution of hCG from Con A, the eluant buffer( 0.5 mol/1 alpha
methylmannoside in PBS starting buffer) was exchanged for 0.02 moll Tris/HC1,
pH 8.0 and the volume reduced from 20 ml to approximately 6 ml.
Materials
1 Amicon micro-filtration unit, 10 ml size (Figure Al)
2 YM 100 DiafloR ultrafilters, molecular weight >10,000 retained
3 0.02 mol/1 Tris/HCl buffer, pH 8.0
4 Nitrogen gas under pressure
Method
1 10 ml Con A eluate reduced under pressure( 10-20 psi) to approximately 2 ml,
volume made up to 10 ml with remaining eluate and procedure repeated until
volume of eluate( originally 20 ml) was approximately 2 ml
2 .02 mol/l Tris/HC1 buffer added to 10 ml mark, volume then reduced under
pressure to approximately 2 ml
3 Step 2 repeated 4 times (ie, reduction/dilution performed 5 times) to complete
buffer exchange
4 Eluant in 0.02 mol/I Tris/HC1 buffer reduced to final volume of approximately 6ml
Loss of hCG in this step was assessed by testing the filtered buffer leaving the
microfiltration unit for hCG and was found to be negligible. In addition, any hCG
escaping through the filter would be of molecular weight <10,000, and so would be
a fragment rather than biologically active hCG dimer.
Completeness of buffer exchange was checked during a pilot study using a Corning
925 Cl- meter( amperometric/coulometric Ag+ titration) and the Cl- content of the
eluate, originally 450 mmol/l, was measured each time the volume was and made ul
to 10 ml with 0.02 mol/l Tris/HCl buffer( Cl concentration 11 mmol/l )with the
following results (Table Al).
From these results the working procedure described above was adopted.
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Figure Al
Microfiltration apparatus
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Table Al
Buffer exchange check
Buffer exchange of PBS starting buffer( Cl- concentration 450mmol/1), for 20
mmol/l Tris/HC1(Cl- concentration 11 mmol/1)
Sample in micro- C1 concentration mmol/1
filtration unit
1 1m1 PR 450
3 ml- 10 ml with Tris/HC1 1st reduction/dilution 150
( 3/10 dilution)
3 ml- 10 ml with Tris/HC1 2nd reduction/dilution 55
( 9/100 dilution)
5 ml- 10 ml with Tris/HC1 3rd reduction/dilution 32
( 1/25 dilution)
1 ml- 10 ml with Tris/HCl 4th reduction/dilution 17
( 1/250 dilution)
5 th reduction/dilution2 ml- 6 ml with Tris/HCl 11
( 1/750 dilution)
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Appendix 3
Detection and Measurement of hCG
A. Detection( semi-quantitiative)of hCG
B. Radioimmunoassay for total beta hCG
C. En.yyme-immunometric assay for di'mer hCG
A. Hybritech Tandem Icon semi-quantitiative test for the detection of
hCG (Hybritech Incorporated, San Diego, California)
This semi-quantitative immunoenzymetric assay is designed for urine and a positive
result is given with an hCG concentration >20 IU/1.
B. RIA for total beta hCG( Diagnostics Product Corporation)
At the beginning of this project facilities and resources for radioimmunoassay of
total beta hCG were immediatly available and this method of quantitating hCG was
therefore used for initial calibration of some of the purification steps.
Materials and Test Specifications
Diagnostic Products Corporation RIA kit for total beta hCG
Packard Autogamma 5780 counter
Results obtained using this method are in IU/l relative to the International Reference
Preparation for Immunoassay.
The stated linearity limit of this test is 200 IU/I with a sensitivity limit of 3 IU/1.
Cross-reaction with other glycoproteins is stated to be negligible (LH cross reaction
0.2%).
Project samples were diluted appropriately in zero calibrator before measurement and
the manufacturer's test protocol followed.
Between-run precision was 11.3% at 30 IU/mi and 7.2% at 200 IU/ml.
C. EIA for dimer hCG
The Hybritech Tandem E test is a solid phase, two-site immunoenzvmetric assay
which is claimed to be specific for dimer hCG. Since this project was intended to
address the thyrotropic biological activity of hCG compared to the immunological
activity, it was felt that an immunoassay designed to measure the biologically active
dimer hCG concentration was more suitable for use than one measuring the total
beta, ie, dimer plus free( inactive) beta subunit, concentration, and this assay
therefore replaced the radioimmunoassay for total beta HCG as soon as was
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practicable. The test was performed using the Hybritech Photon Era for automated
sample addition, washing, substrate addition, reading and calculation of results.
Materials and Test Specifications
Hybritech Tandem E Immunoenzymetric assay kit, comprising the Antibody
Set and the Substrate Set( Hybritech Inc., San Diego, California)
Hybritech Photon Era
The assay is calibrated against the International Reference Preparation of hCG for
immunoassay and the results obtained are reported as IU/l relative to this. The stated
linearity range is up to 400 IU/l and the stated sensitivity is 2 IU/l. Cross-reaction
with the other glycoproteins is reported to be negligible (LH 0.2% cross-reaction).
Project samples were diluted appropriately in zero calibrator or 5% human albumin
solution (no hCG detected) and the manufacturer's test protocol followed.
In-run and between-run precision was as follows:
In-run 25 IU/i CV= 3.8% n=8
300 IU/1 n=8
Between-run 25 IU/1 CV= 7.9% n= 20
300 IU/1 CV= 10.49 n= 20
CV = 3.0%
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Appendix 4
Measurement of creatinine in urine
Creatinine concentrations of the undialysed project urines were measured by the
method of Jaffe using a Chemlab continuous flow analyser.
The flow diagram of the creatinine manifold, the equipment settings and the reagents
used are shown in Figure A2.
All urine samples were diluted in distilled H2O and measured against aqueous
creatinine standards in one run, the CV of which was <1% at 400 umol/l.
The thyrotropic activity ofhCC in women with
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Appendix 5
FRTL-5 bioassay for thyrotropic activity
A Detailed list of chemicals and eauinment used
B Composition of culture media
C Trypsinisation of cells and platin out
D ESTA method for measuring dehydrogenase activity and protein in
FRTL-5 cells
A. Detailed list of chemicals and equipment
For cell maintainance:
1 Coon's modified F 12 medium: Gibco
2 bTSH( Thytropar): Armour Pharmaceuticals
3 Insulin (bovine, sodium): Calibiochem
4 Somatostatin: Calibiochem
5 Glycl-histidyl-lysine acetate: Calibiochem
6 Hydrocortisone: Calibiochem
7 Transferrin: Behring Diagnostics
8 Penicillin/Streptomycin: Gibco
9 Non-essential amino acids: Gibco
10 L-glutamine: Sigma
11 Gentamicin: Pharmacy Dept., UCH
12 New born calf serum: Gibco




17 Chicken serum: Gibco
18 Liquid nitrogen: British Oxygen
For ESTA Staining Method
1 MTT (3-(4,5 dimethylthiazol-2-yl)-2,5,diphenyltetrazolium bromide: Sigma
2 Dulbeccos 'A' phosphate buffered saline, pH 7.3: Oxoid
3 0.014 mol/1. HCl in isopropanol (123 ul HCl 100 ml propan-2-ol)
4 Napthol Yellow S: Aldrich Chemical Co Ltd
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5 Acetic acid 1% v/v
6 0.25 mol/I NaOH
Equipment
1 Petri dishes (Nunc): Gibco
2 Culture plates(Nunc):Gibco
3 10 ml sterile plastic pipettes: Sterilin
4 5 ml sterile plastic pipettes: Sterilin
5 1 ml sterile plastic syringes: Sterilin
6 0.2 u sterilising filters( Flowpore D and Microflow 50): Flow Laboratories
7 Bijou bottles (7 ml): Sterilin
8 Universal bottles( 30 ml): Sterilin
9 Cryotubes: Gibco
10 Eppendorf multi-repeater pipettes
11 Dynatech microtitre plate reader
2 Composition of Culture Media







TSH and insulin are added separately to a 4-hormone mixture,
All hormone stock solutions are stored in liquid N.
6H Constituent Solutions
1 Coon's modified Hanks' F12 medium:
i Dissolve contents of one ampoule of Conn's modified F- 12 medium powder
in one litre of double distilled water
ii Add 2.5g sodium bicarbonate and 1 ml of gentamicin (40 mg/ml)
iii Filter using a pressure vessel( approximately 10psi) into sterile bottles and
store at 4°C
2 TSH
i Thvtronar TSH, 10 IU/vial: dissolve the contents of 1 vial in 10 ml Hanks
159The thyrotropic activity of hCG in women with hyperemesis gravidarum
balanced salt solution to give a 1 IU/ml solution of TSH
ii Store in 100 ul aliquots in liquid N2
3 Insulin
i Add 60 mg insulin in 4 ml Hanks' balanced salt solution
ii Add 400 ul 1 moll NaOH to dissolve
iii Add a further 1.6 ml Hanks' balanced salt solution to give a 10 mg/ml solution
iv Store in 100 ul aliquots in liquid N,
4 Somatostatin
i Dissolve 50 ug somatostatin in 500 ul Hanks' balanced salt solution
ii Make volume up to 5 ml with Hanks' balanced salt solution to give a 10 ug/ml
solution
5 Glycyl-Histidyl-Lysine Acetate (GHL)
i Dissolve 10 mg GHL in 10 ml Hanks' balanced salt solution
ii Take 100 ul of this and make up to 10 ml with Hanks' balanced salt solution
to give a 10 ug/ml solution of GHL
6 Hydrocortisone
i Dissolve 13.5 mg hydrocortisone in 18.5 ml ethanol
7 Transferrin
i Dissolve 25 mg in 5 ml Hanks' balanced salt solution to give a 5 mg/ml solution
8 4 Hormone Mixture (4H)
i To 29.75 ml Hanks balanced salt solution add:
5 ml somatostatin (10 ug/ml)
5 ml glycly-lysyl-histidine acetate (10 ug/ml)
25 ul hydrocortisone( 730 ug/ml)
5 ml transferrin( 5 mg/ml)
ii Store in 1 ml aliquots in liquid N2,
9 Antibiotics
i 10,000 units/ml Penicillin and 10,000 ug/ml Streptomycin mixed
ii 1 ml aliquots of this solution stored at -20°C
iii In use, 1 ml aliquot made up to 100 ml with F12 medium
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10 Non-Essential Aminn Acic
1
Gibco solution of non-essential amino acids x l 00 stored at 4°C in 1 ml aliquots
U
Each 100 ml culture medium receives one 1 ml aliquot
11 Glutamine
1
Dissolve 2.92g glutamine in double distilled water to a final volume of 100 ml
( 200mmo 1)
U 1 ml aliquots of this are stored at -20°C
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In use, one 1 ml aliquot is warmed to 37°C to redissolve the glutamine and then
added to 100 ml culture medium
12 New Born Calf Serum
Heat inactivated new born calf serum is added sterile after medium has been
filtered to give a concentration of 5% v/v
If not heat inactivated, the new born calf serum should be heat treated at 56°C
for 30 minutes to denature the complement
To Make 6H
1 90 ml Coon's modified F12 medium
2 1ml4H
3 100 ul insulin at 10 mg/ml
4 100ul TS H at 1 U/ml
5 1 ml penicillin/streptomycin
6 1 ml glutamine( warmed to 37°C to dissolve)
7 1 ml non-essential amino acids
8 Filter through sterilising filtration unit
9 Add 5 ml sterile new born calf serum
To Make 5H
As for 6H but omit the TSH
3 Trvnsinisation of Cells and Plating Out
Collagenase/Trypsin Mixture( CTC)
1 2,000U collagenase
11 75 mg trypsin
11 2 ml heat inactivated chicken serum
iv 95 ml Hanks' balanced salt solution
V This mixture stored at -20°C in 9 ml aliquots
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vi Filter before use
Trypsinisation and Plating Out
i Filter CTC mixture
ii Add 3 ml CTC to each petri dish of cells and leave in incubator at 37°C for 5
minutes
iii Separate cells by repeatedly aspirating and forcibly ejecting cells through a
pasteur pipette
iv Add 3 ml 6H to each petri dish to dilute the CTC
v Put the cell suspension into a sterile universal container and spin at 1,000 rpm
for 7 minutes
vi Remove the supernatant and resuspend cells in 8 ml 6H, mixing well with a
pasteur pipette
vii Take one drop of cell suspension and count the number of cells in it using a cell
counting chamber
viii Dilute accordingly with 6H to give a cell concentration of 2 x 105 cells/ml for
bioassay
ix Pipette 150 at of this cell suspension into each well of a microculture plate or 5
ml into each petri dish and place in incubator
4 Esta Method for Measuring Dehydrogenase Acitivity and Protein
Levels in FRTL-5 Cells
MTT Stain for Dehydrogenase Activity
i Warm 10 ml Dulbeccos phosphate buffered saline to 37°C
ii Weigh out 50 mg MTT' at room temperature and dissolve in warmed phosphate
buffered saline to give a 5 g/l solution. This solution is made fresh just before
use
iii Using a multi-repeater pipette add 15 ul MTT dye solution to each well of the
microculture plate
iv Tap plate gently and incubate at 37°C for 15 minutes
v Decant stain and medium mixture from microculture plate and blot plate
vi Add 100 ul 0.014 moll HC1/isopropanol to each well
vii Mix gently and use the microtitre plate reader to read the absorbance of the
eluted stain in each well at 570 nm against an air blank with 630 nm reference
viii After reading decant stain, blot and allow plate to dry overnight in dark at room
temperature before proceeding with NYS stain
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NYS Stain for Protein
i
Make up 1% w/v solution of NYS in 1% v/v (0.17 mol/1) acetic acid( stock
NYS)
11
Make up working stain solution by diluting stock 1/10 in 1% v/v (0.17 mol/1)
acetic acid
111
Using a multi-repeater pipette add 100 ul working NYS stain to each well of the
microculture plate
iv
Tap plate gently and leave in the dark room at temperature for 1 hour
V Decant stain and blot plate
V1
Wash plate in each of three 1% (0.17 mol/l) acetic acid solutions for 30 seconds,
5 minutes and 30 minutes in sequence
vii Decant and blot plate
viii
Add 100 ul 0.25 mol/1 NaOH to each well of plate
ix Mix gently and use the microtitre plate reader to read the absorbance of eluted
stain in each well at 450 nm against an air blank and 630 nm reference.
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Appendix 6
Isoelectricfocusing and immunoblottin of hCG
A Preparing the polyacrylamide gel for isoelectricfocusing
B Transfer from gel onto nitrocellulose
C Immunoelectroendosmosis of antisera onto nitrocellulose
A Preparing the polyacrylamide gel for isoelectrofocusinR
Reagents and materials
1 Acrylamide/DATP solution: 19.1% acrylamide in 3.38% DATP (N,N'
diallyl-tartard.iamide) in H2O
2 22.5% sucrose in H2O
3 Ampholines: Ampholyte pH range 3.5- 5.0 (LKB) and Pharmalyte pH range 3
- 10 (Pharmacia)
4 N N N'N' tetramethylethylenediamine (TEMED) (Sigma)
5 Ammonium persulphate: 0.1 g in 10 ml H2O, freshly made
6 Whatman laboratory sealer, 4 x 3 layers (0.45 mm thick) 1 cm wide and joined
with silicone vacumn grease, length cut to fit edges of glass support plate
7 Glass gel support plates, 24 cm x 13 cm
8 LKB plastic gel support sheets, 24 cm x 13 cm
9 Metal clips
10 10 ml plastic syringe
11 Ethanol
12 Roller
13 Small spatula (spacer)
14 Vacumn apparatus for degassing
To make the mold (Figure A3)
1 2 Glass plates and 2 plastic support sheets acetone washed
2 Small amount of ethanol poured onto one glass plate and one plastic support
sheet pressed on top with roller: there should be no air bubbles between glass
and plastic sheets
3 One side of each plastic sheet and one side of one of the glass plates polished
with a small amount of silicone grease
4 1 cm width, 0.45 mm-thick strips of laboratory sealer carefully placed around
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Figure A3
Isoelectricfocusing gel mold
165The thyrotropic activity of hCG in women with hyperemesis gravidarum
the edges of the polished side of the plastic support sheet which is on top of the
glass plate and silicone grease applied to surface of the strips a gap of
approximately 2-3 cm should be left in the upper right side and the spacer put in
this gap
5 Second plastic support sheet, with polished side down, carefully placed on top
of the first plastic support sheet( polished sides should be facing each other)
6 Second glass plate, polished side down, placed on top of second plastic sheet
7 Overlapping metal clips fixed along bottom, both sides and two thirds the length
of the top of the mold: stand mold in vertical position
To make and pour gel( 10% gel, 0.45 mm thick. T/C= 10/15
1 In a 250 ml conical flask mix:
4.0 ml acrylamide/DATP solution
4.0 ml sucrose solution
20 ul TEMED
0.25 ml 3- 10 ampholyte
0.6 ml 3.5- 5.0 ampholyte
2 Degas for approximately 3 minutes
3 While the solution is being degassed, prepare 0.1% ammonium persulphate
solution (1 g/l H2O)
4 Add 0.38 ml fresh ammonium persulphate solution to the degassed solution and
inject into the mold immediately, taking care not to introduce any air bubbles
5 Remove spacer and attach metal clips to the gap
6 Lay flat at room temperature for 20 minutes and then refridgerate
7 Next day, remove metal clips and wrap mold in cellophane film: keep at 4°C
and use within one week
B Transfer from gel onto nitrocellulose (Figure A4)
1 Stock 0.25 moll Tris/borate buffer, pH 8.3
2 Stock Tris/borate buffer, pH 7.2
3 Transfer buffer: 0.08 moll Tris/borate buffer pH 8.3with 5% methanol
4 Blocking buffer: 0.05 mol/1 Tris/borate buffer, pH 7.2 in 0.1% Tween 80
5 Washing buffer: 0.05 moll Tris/borate buffer pH 7.2
6 Transfer tank: Bio-rad Transblot cell
7 Whatman 3 mm chromatography paper, 21 cm x 11 cm
8 Nitrocellulose membrane, LKB 0.45 u pore size, cut to fit gel
9 Cellulose acetate membrane, Schleicher and Schuell, West Germany: cut to be
slightly smaller than nitrocellulose membrane
10 Whatman No 1 filter paper
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Figure A4
Transblot sandwich
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C Immunoelectroendosmosis of antisera on nitrocellulose memhrnrv
Materials
1 Antisera (in appropriate freshly made dilution)
2 Shandon electrophoresis tank with power pack
3 Whatman 3 mm chromatography paper wicks, 11 x 22 cm
4 0.05 mol/l Tris/borate buffer, pH 7.2 in 0.1% Tween 80 (blocking buffer
5 Cellulose acetate membrane applicator strips, 1 x 20 cm
Methc
1 Pour 500 ml fresh blocking buffer into each side of the electrophoresis tank
2 Lay blocking buffer-soaked nitrocellulose membrane from transblot cell across
the tank, anode side at anode, and place edges of wicks over edges of
nitrocellulose: ensure the wicks are well saturated with buffer
3 Place an antiserum-soaked cellulose acetate applicator strip along the length of
the nitrocellulose membrane at the anode edge
4 Apply voltage( 200-300 V) to promote the electroendosmotic buffer wash from
anode to cathode: this will carry with it the antiserum from the cellulose acetate
strip
5 Allow the antigen-antiserum reaction to proceed with continual electro-
endosmosis for
a) 2 hours at 300 V for rabbit anti-hCG (1st antibody)
b) 50 minutes at 200 V for swine anti-rabbit (2nd antibody)
c) 50 minutes at 200 V for rabbit anti-horseradish peroxidase
(3rd antibody)
remove each cellulose acetate applicator strip before applying another one
6 Soak a cellulose acetate applicator strip in peroxidase solution and apply to
anode end: run in at 200 V for 2 hours
7 Remove the cellulose acetate applicator strip from the nitrocellulose membrane,
remove the nitrocellulose membrane from the tank, wash the excess peroxidase
from the strip with distilled water and place the nitrocellulose membrane in fresh
stain solution
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Appendix 7
Patient Datafile for Gestationy T4, TSH, hCGy Urine and Eluate AIM
hCG Ratio, Urine and Eluate AIM hCG Ratio x Serum hCG and
Pregnancy Outcome
No Gestation T4 TSH hCG AM hCG ratio AM hCG ratio Pregnancy
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No
Gestation T4 TSH hCG AM hCG ratio AM hCG ratio Pregnancy
















































































































































nr= no measurable response in bioassay
bioassay performed on first 17 patients' samples only
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